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ABSTRACT
The prevalence of obesity has doubled worldwide since the 1980s, and having a high
body mass index contributes to more deaths worldwide than being underweight. Over the past
20 years, consumption of calorie-dense foods has increased, and this is considered one of the
major causes of the rapid rise in obesity. Thus, understanding the neural control of food intake is
important for the development of new and effective treatments of obesity. Two important brain
regions that regulate food intake are the hypothalamus and the mesocorticolimbic dopamine
system. The hypothalamus is essential for the homeostatic control of feeding and body weight,
while the mesocorticolimbic dopamine system, also known as the reward system, is the primary
circuit for reward and motivated behavior. The reward system also regulates food intake and

food reward, and there is increasing evidence that hypothalamic feeding-related neuropeptides
alter dopamine neuron activity to affect feeding. Nevertheless, how these neuropeptides interact
with the reward system to regulate feeding is not fully understood. For example, centrally
delivered neurotensin and neuropeptide-Y (NPY) increase dopamine release in the nucleus
accumbens, but cause opposite effects on food reward. In addition, injection of the hypothalamic
neuropeptides neurotensin, NPY, or alpha-melanocyte-stimulating hormone (-MSH) into the
ventral tegmental area (VTA), where reward-related dopamine neurons are located, alters
multiple aspects of feeding, but how these neuropeptides interact with the reward system to alter
feeding at both the circuit and cellular levels is not fully understood. In these studies, I have
used whole cell patch-clamp electrophysiology in acute brain slices from mice to examine how
neurotensin, -MSH, and NPY affect VTA dopamine neuron activity. I have demonstrated that
these neuropeptides use multiple mechanisms to alter VTA dopamine neuron activity, including
both pre- and post-synaptic mechanisms. Neurotensin and -MSH increased dopamine neuron
activity, while NPY had both excitatory and inhibitory effects on dopamine neuron activity.
Overall, these studies provide an important advancement in our understanding of the different
mechanisms utilized by hypothalamic neuropeptides to alter VTA dopamine neuron activity and
how hypothalamic neuropeptides interact with the mesocorticolimbic dopamine system to
control food intake and food reward.
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INTRODUCTION AND LITERATURE REVIEW

Obesity is a worldwide epidemic and global health crisis that is on the rise. Obesity
rates have more than doubled worldwide since 19801,2. Obesity and a high body mass index
(BMI) are detrimental to one’s health. A high BMI (overweight: BMI ≥25, obese: BMI ≥30) is
a major risk factor for several diseases such as musculoskeletal disorders, diabetes mellitus,
chronic kidney disease, stroke, cancer, and cardiovascular disease2. Remarkably, being
overweight or obese contributes to more deaths than being underweight worldwide1, and a high
BMI contributed to 4 million deaths and a 120 million disability-adjusted life-years among
adults around the world in 20152. Obesity is not only a substantial health burden but also an
economic burden. An estimated $147 billion was spent on obesity related medical costs in the
United States in 20083. Thus, the global rise in BMI is a substantial problem.
The rise in body weight over the last couple of decades is largely due to an increase in
food consumption4-7. The availability of food has increased over the past several decades, and
calorie-dense foods such as chocolate, cakes, and chips are cheap and abundant4-7. This has
lead to an environment that promotes overeating and weight gain4-7. Understanding the neural
mechanisms that drive the over consumption of food is significantly important for the
development of methods, policies, and treatments that can be used to prevent and reverse weight
gain and obesity.
Two biological systems that regulate food intake are the homeostatic energy system and
the reward system. The homeostatic system comprises hypothalamic and brainstem circuits,
numerous neuropeptides, and hormonal gastrointestinal and fat signals that work together to
control calorie intake and expenditure to maintain energy balance8. Thus, proper function of the
homeostatic energy system should prevent people from gaining weight, and yet in the U.S.,
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there are more overweight and obese people than people with a healthy BMI9-11. In contrast to
the homeostatic system, the reward system or mesocorticolimbic dopamine system, regulates
feeding and body weight by reinforcing behaviors that result in food intake. This especially
holds true for intake of food that is high in fat and sugar, as these foods are highly rewarding
and reinforcing. It has been hypothesized that the reward system overrides the homeostatic
system in an environment rich in rewarding calorie-dense foods, leading to a net positive of
calories consumed over calories burned12. Put simply, people are highly motivated to eat
calorie-dense, sugary/fatty foods even as the homeostatic brain system signals for one to stop
eating. Thus, it is important to understand how the brain’s reward system regulates food intake,
weight gain, and food reward-related behaviors and how the reward and homeostatic systems
interact to regulate these behaviors. The homeostatic control of energy balance encompasses
numerous circuits, hormones, and neuropeptides, and although the homeostatic energy system is
often considered independent of the reward system, the homeostatic energy system does interact
with the reward system to control food intake and body weight. Yet how these two systems
interact is not completely understood. Here I describe our studies testing how three distinct
hypothalamic feeding neuropeptides alter the activity of mesocorticolimbic dopamine neurons
to regulate food intake, body weight, and reward-related behaviors.

1.1

Overview of the mesocorticolimbic dopamine system
Dopamine is a key neurotransmitter that regulates many different behaviors and

physiological processes including motor learning, incentive motivation, reward and
reinforcement, learning, aversion, and food intake and body weight13-18. Furthermore,
disruptions in dopamine circuits are implicated in psychiatric disorders such as Parkinson’s
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disease, schizophrenia, depression, and drug addiction, as well as obesity. The two most
studied populations of dopamine neurons that are involved in these disorders are the dopamine
neurons of the substantia nigra pars compacta (SNc) and of the ventral tegmental area (VTA).
These two populations of neurons are located in the midbrain, and the SNc laterally borders the
VTA with some overlap between the two areas. SNc dopamine neurons are part of the
mesostriatal dopamine system, and predominantly regulate movement and motor coordination
and project to dorsal striatum. VTA dopamine neurons are part of the mesocorticolimbic
dopamine system and predominantly regulate reward and reinforcement behavior and project to
ventral striatum. In addition, as mentioned above, the mesocorticolimbic dopamine system also
regulates food intake, food reward, and body weight, so the studies described here examine how
hypothalamic feeding-related neuropeptides specifically affect VTA dopamine neurons.
The mesocorticolimbic dopamine system comprises not only dopamine neurons in the
VTA but also the afferents inputs to the VTA and the projection targets of the dopamine
neurons. VTA dopamine neurons receive afferent inputs from numerous brain areas including
but not limited to the lateral hypothalamus (LH), ventral pallidum, amygdala, nucleus
accumbens (NAc), cortex, and dorsal raphe nucleus19,20. In addition, dopamine neurons are
innervated by local VTA inhibitory GABA neurons and excitatory glutamate neurons21-23. VTA
dopamine neurons send efferent projections to many brain regions such as the NAc, olfactory
tubercle, hippocampus, amygdala, bed nucleus of the stria terminalis, and prefrontal cortex
(PFC). VTA GABA and glutamate neurons send long-range projections to both distinct and
parallel dopamine neuron efferent sites24-27. The mesocorticolimbic dopamine system is truly a
complex circuit with broad connections.
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The VTA is made up primarily of dopamine neurons (~55-65%), which are defined as
neurons that express tyrosine hydroxylase, the enzyme for catecholamine production28,29. The
rest of the VTA is comprised of GABA and glutamate neurons. Approximately 20-35% are
identified as GABA neurons and 2-3% as glutamate neurons28,30,31. Interestingly, a small
portion of VTA neurons co-release both glutamate and GABA32-34. Dopamine neurons were
once thought to be a uniform population, but recent studies show that the VTA contains a
heterogeneous dopamine neuron population. Distinct subpopulations of dopamine neurons have
been identified by their power to control distinct behaviors and by a variety of distinct
characteristics such as projection site, electrophysiological properties, pharmacological
properties, and molecular markers16,17,35,36. In addition, a subpopulation of VTA dopamine
neurons co-releases GABA37,38, and another population co-releases glutamate39-41. Thus, VTA
dopamine neurons are not one distinct neuronal group but a mixture of multiple neuronal groups
that express dopamine.
1.1.1

The mesocorticolimbic dopamine system and reward behavior
The role of dopamine in reward and reinforcement behavior is well established. Our

first knowledge of the brain circuitry regulating reward behavior came from Olds and Milner’s
famous 1954 study demonstrating that rats will learn to lever press for electrical stimulation of
specific brain regions (intracranial self-stimulation or ICSS)42. Several studies in the 1970s
revealed the importance of dopamine for the regulation of reward behavior as injection of
dopamine receptor antagonists decreases ICSS in rats43-48. After these initial studies, a detailed
description of how dopamine regulates reward behavior soon emerged from a number of
experiments (for review see14,15,18,49-51).
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Dopamine acts as a salient signal or learning cue that reinforces or “stamps in”
behaviors and responses that lead to rewards, and these learned behaviors are repeated until that
behavior no longer leads to an obtained reward14,15,49. Dopamine acts as a learning cue, because
dopamine neuron activity and dopamine release increase in response to a reward. Dopamine
neurons fire tonically, but in response to an unexpected reward such as food, water, or sex
dopamine neurons fire in bursts causing an increase in dopamine release14,15,18,49-51. If a cue
consistently predicts a reward, then the timing of dopamine neuron burst firing will shift to the
cue predicting the reward18,50,51. Dopamine neuron firing and dopamine release also increase if
a reward is greater than predicted, but there is a decrease or pause in firing and dopamine
release if an expected reward is less than predicted or not obtained18,50,51. Thus, dopamine acts
as a reward prediction error that encodes the deviation between what is predicted and what is
actually obtained18,50,51.
1.1.2 Dopamine neuron tonic and burst firing
Grace and Bunny first characterized the activity states of dopamine neurons 35 years
ago and identified three different activity states of midbrain dopamine neurons: silent and
hyperpolarized, slow pacemaker firing (2-10 Hz)/irregular firing, and phasic burst firing52-58.
These first studies were primarily conducted on anesthetized and unanesthetized paralyzed rats
in vivo, and were later confirmed in unanesthetized behaving rats59,60. The slow pacemaker
firing or “tonic firing” of dopamine neurons causes tonic release of dopamine at efferent target
sites, and burst firing causes a phasic increase in dopamine release61-63 which is triggered by
rewards and cue-associated rewards18,50,51. This phasic release of dopamine is what encodes the
reward prediction error discussed above. Since the first studies by Grace and Bunney
illuminating the firing characteristic of dopamine neuron activity, extensive research has been
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conducted aimed at understanding how dopamine neuron activity is controlled and how
dopamine neurons transition from a tonic to a bursting state.
Spontaneous pacemaker firing in VTA dopamine neurons is primarily dependent on two
Na+ currents: a tetrodotoxin (TTX) insensitive Na+ leak current, and a TTX-sensitive voltagedependent Na+ current64,65. In contrast, spontaneous pacemaker firing in SNc dopamine neurons
is primarily dependent on Ca2+ currents and a Ca2+-activated K+ current, while pacemaker firing
in VTA dopamine neurons is comparatively unaffected by Ca2+ channel blockers64-66. The
transition from slow pacemaker firing to burst firing is regulated by afferent inputs to dopamine
neurons. In fact, dopamine neurons in vitro fire at a slow pacemaker rate but do not burst fire,
indicating the critical importance of afferent inputs for burst firing67,68. Afferent inputs to
dopamine neurons are critical for burst firing but do not act in isolation; rather, they interact
with cellular conductances to generate bursts. For example, Ca2+ is a key component for the
generation of bursts, as chelating intracellular Ca2+ with EGTA has been shown to prevent burst
firing, whereas intracellular injection of Ca2+ increases burst firing57. It is hypothesized that
Ca2+ conducted through excitatory NMDA receptors (NMDAR) and voltage-gated Ca2+
channels are key to generating bursts in VTA dopamine neurons57,69.
Glutamatergic synaptic input to dopamine neurons is sufficient and necessary for burst
firing. For example, locally applied glutamate to midbrain dopamine neurons increases burst
firing57, and central or intra-midbrain injected antagonists of fast ionotropic glutamate receptors
abolishes burst firing70,71. Previous work indicates that the glutamatergic inputs driving burst
firing primarily originate from the PFC, pedunculopontine nucleus, and the subthalamic
nucleus, as stimulation of these brain regions causes burst firing in midbrain dopamine
neurons63,72-76. Numerous pharmacological studies suggest that the ionotropic glutamate
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receptor, NMDAR, is responsible for glutamate-induced burst firing. Indeed, intra-midbrain
NMDAR agonists increase bursting, whereas NMDAR antagonists decrease spontaneous and
evoked bursting in vivo75,77-79. In addition, genetic inactivation of NMDARs in midbrain
dopamine neurons decreases burst firing80. In contrast, agonists and antagonists to the
ionotropic glutamate AMPA receptor (AMPAR) do not affect spontaneous or evoked burst
firing in midbrain dopamine neurons75,78,79. Nevertheless, AMPAR agonists do increase the
firing rate of dopamine neurons78, and an increase in firing rate is highly correlated with burst
firing57.
GABAergic afferents are also an important regulator of dopamine neuron firing.
Midbrain dopamine neurons are innervated by GABAergic neurons from the striatum, globus
pallidus, rostromedial tegmental nucleus, ventral pallidum, and NAc19,81-85, as well as local
GABAergic interneurons21,23. Numerous pharmacological studies examining the role of GABA
in regulating dopamine neuron firing have shown the importance of GABAergic synapses and
GABA receptors. GABA inhibits dopamine neurons through two receptors: fast ionotropic
GABAA receptors (GABAAR), and slow metabotropic GABAB receptors (GABABR) that
activate G-coupled inward rectifying potassium (GIRK) channels. Midbrain application of
GABAAR antagonists causes a shift from slow irregular/pacemaker firing to burst firing and
increases the overall firing rate of dopamine neurons, while GABABR antagonists shift the
number of dopamine neurons firing in a slow irregular pattern to a pacemaker-firing pattern86,87.
In addition, removing a GABAAR conductance after applying a constant NMDAR and
GABAAR conductance in vitro drives dopamine neuron burst firing, demonstrating that removal
of GABAAR input can drive burst firing88. In contrast, systemic and intra-midbrain injected
GABABR agonists decrease firing rate and burst firing89-91, and GABAAR and GABABR
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agonists block spontaneous tonic firing and NMDA-induced burst firing in dopamine neurons in
vitro88,92,93. Lastly, GABAergic transmission may also contribute to pauses in dopamine neuron
burst firing in behaving animals69. Pauses in firing occur in behaving animals when an expected
reward is not obtained, and as dopamine neurons are abundantly innervated by GABAergic
afferents, GABA is a likely candidate for mediating these pauses. Indeed, increasing GABAAR
conductance causes a pause in tonic dopamine neuron firing88. However, a decrease in
excitatory glutamate transmission may also contribute to dopamine neuron pauses69, as removal
of NMDAR conductance also causes a pause in tonic firing88. Thus, GABAergic afferents are
an important regulator of dopamine neuron activity and burst firing.
In addition to fast ionotropic glutamate and GABA receptors, dopamine neurons express
slow metabotropic receptors such as the GABABR mentioned above and the metabotropic
glutamate receptor (mGluR). These slow acting metabotropic receptors also play a role in the
regulation of dopamine neuron firing. For example, along with the pauses in firing that occur in
dopamine neurons in behaving animals, pauses also occur after spontaneous burst firing in vivo
and evoked burst firing in vitro, and it is hypothesized that mGluRs mediate the pause following
spontaneous in vivo and evoked in vitro bursts66,69,94. Indeed, stimulation of midbrain
glutamatergic afferents using a current pulse train protocol that mimics burst firing causes a
slow acting inhibitory post-synaptic current (IPSC) in dopamine neurons that is mediated by
mGluRs94. This mGluR IPSC occurs because activation of mGluRs activates the PLC pathway,
causing Ca2+ release from intracellular stores and subsequent activation of an inhibitory current
mediated by small-conductance Ca2+-dependent K+ (sK) channels94. Thus, glutamate activates
ionotropic and metabotropic receptors causing dopamine neurons to burst fire, followed by
mGluR induced-hyperpolarization and a pause in firing66,94. In addition, activation of other
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metabotropic receptors coupled to the PLC pathway can also cause sK channels to open through
a rise in intracellular Ca2+ and thus may also mediate the pause following a burst66.
Another important metabotropic receptor that regulates dopamine neuron activity is the
dopamine D2 receptor (D2R). Dopamine neuron firing causes local midbrain release of
dopamine from the soma and dendrites of dopamine neurons95-99, and this somatodendritic
release inhibits neighboring dopamine neurons through D2R mediated activation of GIRK
channels98,100-102. Thus, tonic dopamine neuron firing and dopamine release in the midbrain
decreases the activity of dopamine neurons, and burst firing causes an even greater decrease in
dopamine neuron activity. Indeed, evoking dopamine release in vitro causes a D2R mediated
IPSC and pause in tonic pacemaker firing in midbrain dopamine neurons98, and systemic
injection of a D2R agonist decreases evoked dopamine release in the NAc in vivo103. In
contrast, systemic and midbrain injection of D2R antagonists increases the firing rate of
midbrain dopamine neurons in vivo104,105. It has also been hypothesized that D2R activation
terminates bursts of action potentials and is responsible for the pause following spontaneous in
vivo and evoked in vitro bursts in midbrain dopamine neurons98. Indeed, evoking midbrain
dopamine release causes a pause in dopamine neuron firing98, and inhibition of D2Rs abolishes
spontaneous pauses in dopamine neuron firing in vitro106. Thus, D2Rs are key regulators of
dopamine neuron activity and dopamine release.
1.1.3 Synaptic plasticity in VTA dopamine neurons
The idea that dopamine neurons express experience-dependent plasticity was first
supported by behavioral studies in animals repeatedly exposed to cocaine and amphetamine107.
For example, animals repeatedly exposed to cocaine and amphetamine develop increased
locomotor responses to these drugs known as behavioral sensitization, and intra-VTA injected
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NMDAR antagonists prevent the development of cocaine induced locomotor sensitization in
rats107,108. In addition, systemically injected cocaine causes increased glutamate levels in the
VTA109, and NMDAR antagonists block cocaine induced conditioned place preference in
rats110. Taken together, these early studies (and numerous others not mentioned here) suggested
that plasticity at excitatory synapses on VTA dopamine neurons is important for the
development of behavioral sensitization to drugs.
The first study to show that VTA dopamine neurons express plasticity was by Bonci and
Malenka in 1999111. They showed that NMDAR dependent long-term potentiation (LTP) can
be induced at excitatory glutamate synapses on VTA dopamine neurons using a stimulus pairing
protocol used to induce LTP in CA1 hippocampal neurons111. Shortly thereafter, Ungless et al.
(2001) demonstrated that excitatory synapses at VTA dopamine neurons are strengthened in
rodents after a single exposure to cocaine112. Rodents exposed to cocaine exhibit a greater ratio
of AMPAR to NMDAR excitatory post-synaptic currents (EPSCs) and larger AMPAR currents
in VTA dopamine neurons compared to saline treated controls112. This cocaine-induced
plasticity is due to insertion of AMPARs lacking the GLuA2 subunit at the post-synaptic
membrane113. Midbrain dopamine neurons also exhibit LTP of NMDAR-mediated currents,
independent of AMPARs currents114-117. Corticotropin-releasing factor potentiates NMDAR
currents117, and applying a train of afferent stimulation that is paired with evoked post-synaptic
burst firing also potentiates NMDAR currents in dopamine neurons114. This form of electrically
evoked NMDAR LTP is dependent on enhancement of burst-induced Ca2+ signals114. Ca2+
signals are enhanced by activation of PLC coupled metabotropic receptors (such as mGluRs)
and the subsequent release of Ca2+ from intracellular stores114. Interestingly, VTA dopamine
neurons are less sensitive to NMDAR LTP than SNc dopamine neurons, but NMDAR LTP in
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VTA dopamine neurons is sensitized after exposure to amphetamine or social isolation through
a PKA dependent mechanism115,116. Thus, glutamatergic synapses on VTA dopamine neurons
exhibit different forms of LTP.
Glutamatergic synapses on VTA dopamine neurons also exhibit long-term depression
(LTD), and there are two known mechanisms of this glutamatergic LTD. Stimulating afferents
in the VTA at 1 Hz repeatedly with small depolarization triggers Ca2+-dependent LTD at
excitatory synapses on dopamine neurons118,119. However, this form of LTD is not dependent
on NMDARs or mGluRs, suggesting that Ca2+ most likely enters the cell through voltage-gated
Ca2+ channels118,119. Applying brief bursts of afferent stimulation can also evoke LTD, but this
form of LTD is dependent on activation of mGluRs120. mGluR dependent LTD occurs through
an exchange of GluA2-lacking calcium permeable AMPARs for GluA2-containing calcium
impermeable AMPARs120. Thus, LTD occurs at glutamatergic synapses on VTA dopamine
neurons through different mechanisms.
GABAergic synapses on VTA dopamine neurons also exhibit plasticity. For example,
guinea pigs chronically treated with morphine exhibit potentiation of GABAergic synaptic
transmission at VTA dopamine neurons during morphine withdrawal121, and a single exposure
to ethanol has also been shown to potentiate GABAergic synaptic transmission122. In addition,
repeated cocaine exposure depresses GABAergic synaptic transmission at VTA dopamine
neurons123. GABAergic synaptic plasticity at VTA dopamine neurons can also be induced in
vitro. For example, GABAergic transmission is depressed after brain slices containing the VTA
are exposed to opioids23,121, and high frequency stimulation of VTA afferents also induces LTP
of GABAergic synapses through a pre-synaptic increase in GABA release124. Interestingly,
although this form of LTP occurs through a pre-synaptic mechanism, it is dependent on post-
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synaptic Ca2+, NMDARs, and generation of nitric oxide, a retrograde signal124. This form of
GABAergic LTP is blocked after in vivo exposure to morphine124, and after exposure to
cocaine, nicotine, or a stressful stimulus in rats125. Thus, GABAergic synapses on VTA
dopamine neurons can undergo both LTP and LTD through different mechanisms.
D2R and GABAB IPSCs also exhibit plasticity in midbrain dopamine neurons. As
mentioned above, D2R and GABABR activation causes an IPSC by opening GIRK channels in
VTA dopamine neurons. Low frequency electrical stimulation in the VTA/SNc causes LTD of
stimulus evoked D2R IPSCs in vitro126. Interestingly, low frequency stimulation also causes a
depression of evoked GABABR IPSCs, but only a short-term depression as the IPSC eventually
recovers126. LTD of D2R IPSCs is dependent on intracellular Ca2+ and occurs through
desensitization of D2Rs126. The IPSCs generated by GABA acting on GABABRs and dopamine
acting on D2Rs can also be potentiated, and unlike LTD of the D2R IPSC, this form of
plasticity does not affect the D2R but rather the GIRK channels activated by D2Rs and
GABABRs127. Plasticity of GIRK channels is dependent on the firing state of VTA dopamine
neurons127. High-frequency stimulation that mimics burst firing or depolarization in VTA
dopamine neurons potentiates GABABR and D2R currents, whereas stimulating dopamine
neurons with a frequency that mimics tonic firing decreases GABABR currents127. Taken
together, it is apparent that dopamine neurons express plasticity at many different synapses, and
many different synaptic currents exhibit LTP and LTD through both pre- and postsynaptic
mechanisms.
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1.2

The mesocorticolimbic dopamine system and feeding
There are many factors that control when we eat, how much we eat, and what we eat.

For example, internal metabolic signals from the gut signal one’s energy state so that food
intake and metabolism are adjusted based on one’s energy demands. Nevertheless, many other
factors besides energy state trigger food intake and control the types of food eaten; stress,
environmental cues, social factors, and food availability can all play a role. Life experience will
tell one that this is true, but this has also been demonstrated experimentally. Satiated rats feed
in response to a cue previously associated with food, demonstrating that the energy state of the
animal is not the only factor influencing the initiation of feeding128. Satiated rats will also
endure noxious cold or foot shock to eat highly palatable food such as cake, meat pâté, soda,
peanut butter, or candy, even when standard chow is freely available in a neutral
environment129,130. Thus, animals are highly motivated to obtain palatable food, and dopamine
is essential for reward and reinforcement behavior. For example, food deprived rats will lever
press for palatable food even when standard chow is available, but will consume standard chow
rather than lever press for the more palatable food when systemically treated with a dopamine
D1 receptor (D1R) antagonist, or when a D1R or D2R antagonist is injected into the NAc131,132.
Overall, it is clear that many factors control when to eat and what is eaten, and the
mesocorticolimbic dopamine system is critical for reinforcement behavior and the motivation to
work for food.
There are many studies showing the importance of dopamine not only for food
reinforcement behavior but also for feeding. Indeed, dopamine deficient mice are aphagic and
will starve to death by 4 weeks of age if they are not treated with L-DOPA, a dopamine
precursor133, and peripheral injection of the D2R antagonist pimozide decreases free feeding and
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food reward in rats134,135. In addition, free feeding and lever pressing for food increase
dopamine release in the NAc in food-restricted rats136-138. Similarly, dopamine injection into
the NAc increases food and water intake, while D2R antagonism blocks dopamine induced
feeding139, and injecting low doses of amphetamine into the accumbens to stimulate dopamine
release increases food intake, while higher doses decrease food intake140. The importance of the
reward system in feeding behavior has also been demonstrated in humans; for example,
Parkinson’s patients treated with dopamine agonists develop compulsive eating habits141, and in
human imaging studies there is an increase in activity in brain reward areas in response to
pictures of food, and an even greater response to pictures of high-calorie palatable foods
compared to low-calorie foods142. In addition, striatal D2R levels are lower in obese individuals
compared to lean individuals143, and brain reward areas of obese individuals show greater
increases in activity in response to pictures of palatable food than in lean individuals144-147.
Interestingly, there is decreased activity in brain reward areas in obese individuals in response
to food consumption compared to lean individuals144, and weight gain in women causes
decreased activity in the striatum after palatable food consumption148. Thus, the
mesocorticolimbic dopamine system is clearly an important regulator of feeding behavior, and it
is essential to understand how the reward system regulates feeding, food reward, and weight
gain, as the circuitry and function of the reward system appears to be altered in obese
individuals.
1.2.1 Homeostatic regulators of energy balance and interactions with the mesocorticolimbic
dopamine system
The homeostatic control of energy balance encompasses neural circuits, neuropeptides,
and hormonal adipose and gastrointestinal signals that coordinate to balance energy intake with
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energy expenditure to maintain energy equilibrium8. Thus, the homeostatic system increases
food intake and decreases metabolic rate during an energy deficit and decreases food intake and
increase metabolic rate during an energy surplus. Previous studies suggest that the homeostatic
energy system interacts with the mesocorticolimbic dopamine system to regulate food intake
and body weight. For example, the activity of brain reward areas and dopamine release in the
NAc and VTA change with energy state. Indeed, chronically food restricted underweight rats
have lower basal dopamine levels in the NAc149,150. Food restriction increases dopamine release
in the NAc during feeding151-153 and during a sucrose binge in rats154. In addition, food
restriction increases the effects of drugs of abuse155, the locomotor response to dopamine
receptor agonists156,157, and operant responding for cocaine158 and food159. Acute food
restriction also increases evoked somatodendritic release of dopamine in the VTA160, and
chronic food restriction increases burst firing and glutamatergic transmission in SNc dopamine
neurons161. In human imaging studies, fasting increases the response of brain reward areas to
pictures of highly palatable food and the subjective appeal of highly palatable food162. Thus,
the reward system is affected by energy state, which may be due to homeostatic regulators of
energy balance acting on the mesocorticolimbic dopamine system.
The hypothalamus is one of the primary brain areas of the homeostatic energy system
that integrates peripheral satiety signals to regulate energy intake and body weight8,163. The
hypothalamus is composed of distinct nuclei including the arcuate nucleus, ventromedial
nucleus, dorsomedial nucleus, LH, and paraventricular nucleus, among others8,163. There is
extensive evidence that the hypothalamus and mesocorticolimbic dopamine system interact to
regulate food intake and food reward. Neurons of different hypothalamic nuclei project to brain
areas of the reward system and vice versa19,20,163-165. For example, the LH is a key interface
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connecting the hypothalamus with the mesocorticolimbic dopamine system, because the LH
heavily innervates the mesocorticolimbic dopamine system and is connected to other
hypothalamic nuclei163,166. The LH is also an important regulator of food intake and reward
behavior163,166. Indeed, stimulation of the LH elicits feeding and causes an increase in
dopamine release in the NAc136, and peripheral injection of a dopamine receptor antagonist
blocks LH stimulated feeding167. Thus, the LH may serve as a key connection between the
circuits controlling homeostatic and reward feeding.
1.2.2 Hypothalamic feeding-related neuropeptides and interactions with the
mesocorticolimbic dopamine system
Multiple classes of neurons in different hypothalamic regions produce orexigenic and
anorexigenic neuropeptides that regulate energy balance8,163,168. Evidence suggests that these
hypothalamic feeding-related neuropeptides can interact with the mesocorticolimbic dopamine
system to regulate food intake and food reward168. For example, VTA dopamine neurons
express receptors for many of these hypothalamic neuropeptides, and numerous studies have
shown that hypothalamic neuropeptides modulate VTA dopamine neuron activity through
multiple mechanisms, such as directly activating currents in dopamine neurons and/or by
modulating excitatory and inhibitory inputs to dopamine neurons168. In addition, intra-VTA or
NAc injection of several hypothalamic feeding-related neuropeptides alters food intake, food
reward, and other feeding-related behaviors168. The interaction between hypothalamic feeding
neuropeptides and the mesocorticolimbic dopamine system may be an important linkage
between energy state and the motivational state of an animal. Nevertheless, how hypothalamic
neuropeptides and the reward system interact to regulate feeding and food reward is not fully
understood. For example, centrally injected neurotensin or neuropeptide-Y (NPY) both
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increase dopamine release in the NAc, but cause opposite effects on the motivation for food168.
In addition, injection of the hypothalamic neuropeptides neurotensin, alpha-melanocytestimulating hormone (-MSH), or NPY into the VTA alters multiple aspects of feeding169-175,
but how these neuropeptides interact with the mesocorticolimbic dopamine system to alter food
intake, food reward, and weight gain at both the circuit and cellular levels is not fully
understood. Thus, in these studies I have tested how three distinct hypothalamic feeding-related
neuropeptides, neurotensin, α-MSH, and NPY, affect VTA dopamine neuron activity to further
elucidate how these peptides interact with the mesocorticolimbic dopamine system to regulate
feeding and other dopamine dependent behaviors.
1.2.2.1 Neurotensin
Neurotensin is a tricapeptide that is widely expressed in both the central and peripheral
nervous systems. Neurotensin regulates many different physiological processes and behaviors
including analgesia, blood pressure, body temperature, locomotor behavior, drinking, feeding,
and drug intake. There is substantial evidence that neurotensin interacts with the VTA to
regulate dopamine-dependent behaviors. For example, neurotensin expressing neurons project
to the VTA, primarily from the LH and the medial and lateral preoptic areas,176-178, neurotensin
positive fibers heavily innervate midbrain dopamine neurons179,180, and VTA neurons express
neurotensin receptors181-187. Intra-VTA neurotensin increases locomotor activity188,189, induces
conditioned place preference190,191, and rats will operant respond for intra-VTA infusions of
neurotensin192. In addition, activation of neurotensin LH neurons increases locomotor activity
and dopamine release in the NAc193.
Extensive evidence shows neurotensin regulates food intake and food reward. Central
and peripheral injection of neurotensin decreases food intake in both fasted and fed rodents194-
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, and neurotensin antagonism or knockout of the neurotensin receptor NTS1 blocks the

anorectic effects of leptin197,198. Intra-VTA injection of neurotensin increases latency to eat,
reduces food intake, and reduces operant responding for food169-171. Interestingly, ablation of
VTA NTS1 receptor expressing neurons in adult mice reduces body weight but increases food
intake compared to control mice187. Previous studies suggest neurotensin signaling in the VTA
modulates feeding and other dopamine dependent behaviors through an increase in dopamine
neuron activity and dopamine release188,199-207. However, how neurotensin increases dopamine
neuron activity is not fully understood.
1.2.2.2 NPY
NPY is abundantly expressed throughout the body and central nervous systems. NPY
regulates many different behaviors and physiological process including anxiety, pain, stress,
cardiovascular function, circadian rhythms, and feeding; in addition, NPY has also been
implicated in many diseases including obesity, depression, and alcoholism208. NPY is
expressed centrally in the hippocampus, amygdala, locus coeruleus, NAc, cerebral cortex, and
hypothalamus209,210. Within the hypothalamus, NPY is most abundantly expressed in agoutirelated protein/NPY (AgRP/NPY) neurons of the arcuate nucleus209,210. NPY is a strong
orexigenic neuropeptide and regulator of body weight. Indeed, central administration of NPY
or activation of AgRP/NPY neurons causes robust feeding in rodents211-213. In addition,
ablation of AgRP/NPY neurons reduces food intake and body weight214,215, and NPY knockout
decreases fasting-induced feeding216. Substantial evidence suggests that NPY also interacts
with VTA neurons to affect feeding. For example, intra-VTA NPY increases motivation for
food174. In addition, NPY receptors are expressed in the VTA217,218, and NPY decreases the
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firing rate of VTA neurons217. However, how NPY decreases VTA dopamine neuron activity is
unknown.
1.2.2.3 -MSH
-MSH is a peptide hormone that regulates multiple physiological functions throughout
the body including pigmentation, inflammation, pain, and sexual arousal. -MSH is also an
anorexigenic neuropeptide and an important regulator of energy homeostasis and body weight.
Within the brain, -MSH is found in pro-opiomelanocortin (POMC) expressing neurons of the
arcuate nucleus of the hypothalamus and is a derivative of the propeptide POMC. The central
actions of α-MSH (as well as β- and γ-MSH) are mediated by the centrally expressed
melanocortin receptors, melanocortin-3 receptor (MC3R) and melanocortin-4 receptor
(MC4R)165. Collectively, α-, β-, and γ-MSH from POMC neurons, MC3/4Rs, and AgRP (an
inverse agonist to the MC3/4Rs) from AgRP/NPY neurons make up the melanocortin system165.
Numerous studies have shown the importance of the melanocortin system and -MSH for the
homeostatic regulation of energy balance. For example, activation of POMC neurons or
injection of MC3/4R agonists suppresses food intake211,219,220, and knockout of the MC3/4Rs is
associated with obesity, increased fat mass, and reduced activity221. In addition, there is
evidence that -MSH interacts with VTA neurons to regulate food intake, food reward, and
other dopamine-dependent behaviors. For example, POMC neurons project to the VTA222, and
MC3/4Rs are expressed in the VTA223-226, although the literature indicates that MC3Rs are the
primary melanocortin receptor expressed in the VTA with little expression of MC4Rs223,225,226.
Intra-VTA -MSH increases grooming, rearing, and locomotor behavior227-230, and intra-VTA
MC4R agonist decreases ethanol intake231. In addition, we previously showed that intra-VTA
MTII (-MSH analog) decreases food and sucrose intake and operant responding for sucrose
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pellets, while intra-VTA SHU9119 (MC3/4R antagonist) increases food intake and operant
responding for sucrose pellets172,173,175. Chronic blockage of MC3/4Rs with SHU9119 also
increases body weight172. Intra-VTA -MSH increases dopamine turnover in the NAc,
suggesting that -MSH modulates food intake and dopamine-dependent behaviors through an
increase in dopamine neuron activity228-230,232,233. However, the cellular mechanism underlying
the effect of intra-VTA MC3/4R agonists on food intake and reward behavior is unknown.

1.3

Summary of Introduction
Overall, the neural control of food intake and body weight is not fully understood.

Determining the neural mechanisms of food intake is crucial for developing new and effective
treatments for weight gain and obesity, as the global rise in obesity has largely been contributed
to increased food consumption. Presented here are two important central systems that regulate
food intake and body weight, the hypothalamus and the mesocorticolimbic dopamine system.
The hypothalamus primarily regulates homeostatic feeding while the mesocorticolimbic
dopamine system primarily regulates reward-based feeding. Thus, the hypothalamus and
reward system are often studied independently of one another; yet substantial evidence suggest
that they do interact to regulate food intake and food reward. Thus, I describe here our studies
testing how the hypothalamic feeding-related neuropeptides neurotensin, NPY, and, -MSH
regulate VTA dopamine neuron activity to advance our understanding of how the hypothalamus
and mesocorticolimbic dopamine system interact to regulate food intake and food reward.

21

2

OVERALL MATERIALS AND METHODS

For the below experiments I used whole-cell patch clamp and loose-cell attached
electrophysiology in brain slices containing the VTA from mice160,234-236 to test how
hypothalamic neuropeptides affect dopamine neuron activity. Electrophysiological recordings
were collected using an Axon multiclamp 700B microelectrode amplifier and Axograph
software160,234,236. Putative dopamine neurons were identified by their location relative to the
medial terminal nucleus of the accessory optic tract, presence of hyperpolarization-activated
cation currents, spontaneous slow pacemaker firing (≤ 10 Hz), broad action potential waveform
(≥ 1.2 ms), and sensitivity to dopamine68,237-240. Data were stored and analyzed using Axograph
X (v1.3.5), LabChart (v7.3.6; ADInstruments), and Excel (v14.0; Microsoft Corporation)
software. Statistics were calculated using SigmaStat (v11.0; Systat Software, Inc.).
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K. Stuhrman, A.G. Roseberry (2015) Neurotensin inhibits both dopamine- and GABA-mediated
inhibition of ventral tegmental area dopamine neurons. Journal of Neurophysiology, 114(3):
1734-45
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3

NEUROTENSIN INHIBITS BOTH DOPAMINE AND GABA MEDIATED
INHIBITION OF VENTRAL TEGMENTAL AREA DOPAMINE NEURONS

3.1

Abstract
Dopamine is an essential neurotransmitter that plays an important role in a number of

different physiological processes and disorders. There is substantial evidence that the
neuropeptide neurotensin interacts with the mesolimbic dopamine system and can regulate
dopamine neuron activity. In these studies we have used whole-cell patch clamp
electrophysiology in brain slices from mice to examine how neurotensin regulates dopamine
neuron activity by examining the effect of neurotensin on the inhibitory post-synaptic current
generated by somatodendritic dopamine release (D2R IPSC) in ventral tegmental area (VTA)
dopamine neurons. Neurotensin inhibited the D2R IPSC and activated an inward current in
VTA dopamine neurons that appeared to be at least partially mediated by activation of a
transient receptor potential C-type channel. Neither the inward current nor the inhibition of the
D2R IPSC was affected by blocking PKC or calcium release from intracellular stores, and the
inhibition of the D2R IPSC was greater with neurotensin compared to activation of other Gqcoupled receptors. Interestingly, the effects of neurotensin were not specific to D2R signaling
as neurotensin also inhibited GABAB inhibitory post-synaptic currents in VTA dopamine
neurons. Finally, the effects of neurotensin were significantly larger when intracellular Ca2+
was strongly buffered, suggesting that reduced intracellular calcium facilitates these effects.
Overall, these results suggest that neurotensin may inhibit the D2R and GABAB IPSCs
downstream of receptor activation, potentially through regulation of G-protein coupled inwardly
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rectifying potassium channels. These studies provide an important advance in our
understanding of dopamine neuron activity and how it is controlled by neurotensin.

3.2

Introduction
Dopamine (DA) is an essential neurotransmitter involved in many different behaviors

including motor behavior, incentive motivation, reward and reinforcement, learning, memory,
drug intake, and habit formation15, and disruptions in DA signaling have been implicated in
many disorders such as drug addiction, obesity, Parkinson’s disease, and
schizophrenia13,58,164,241,242. Most DA producing neurons are found in the ventral tegmental area
(VTA) and the substantia nigra pars compacta (SNc) of the midbrain15. At rest VTA/SNc DA
neurons fire tonically (2-10 Hz) causing a baseline low level of DA at efferent target sites, but
in response to a reward DA neurons fire in bursts causing phasic increases in DA release58,66,69.
Phasic increases in DA release at efferent target sites are thought to be a salient signal and
learning cue58,66,69. DA burst firing is primarily controlled by glutamatergic afferent inputs, but
DA neuron activity can also be modulated by other neurotransmitters and neuropeptides acting
either directly on DA neurons or indirectly through regulation of GABAergic or glutamatergic
inputs to DA neurons58,66,69. Characterizing how DA neuron activity is regulated is important
for understanding the function of DA under normal and pathological conditions.
In addition to releasing DA from their axon terminals, DA neurons release DA locally
within the VTA/SNc from their soma and dendrites95-99. This somatodendritic DA release
inhibits neighboring DA neurons through dopamine D2 receptor (D2R) mediated activation of
G-coupled inward rectifying potassium (GIRK) channels98,100-102. D2Rs in VTA DA neurons
regulate DA neuron activity and also regulate DA mediated behaviors. For example, injection
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of quinpirole, a D2R agonist, directly into the VTA causes conditioned place aversion, blocks
food induced conditioned place preference, decreases food intake, and decreases cocaineinduced reinstatement243,244. Furthermore, selective knockout of autoreceptor D2Rs within
midbrain DA neurons causes increased motor activity to a novel environment, increased food
self-administration, and increased responses to cocaine such as increased locomotor activity and
conditioned place preference compared to wild type mice245,246. In addition, DA neuron burst
firing is followed by a pause, and it has been proposed that D2R mediated inhibition terminates
bursts of action potentials and is responsible for the pause following burst firing98. Thus, this
autoinhibitory D2R signaling in the VTA plays an important role in the regulation of DA
activity and DA mediated behaviors.
Neurotensin is a tricapeptide that was first isolated and characterized from bovine
hypothalamus247, and is widely expressed in both the central and peripheral nervous systems.
The actions of neurotensin are mediated by three known neurotensin receptors: NTS1, NTS2,
and NTS3 (for review see248). There is abundant evidence that neurotensin interacts with the
DA system (for review see184), and dysregulation of these interactions has been proposed to be
involved in pathologies such as schizophrenia, drug abuse, and Parkinson’s disease184,249-251.
Fibers containing neurotensin heavily innervate midbrain DA neurons179,180, and DA neurons of
the VTA and SNc express neurotensin receptors, primarily the NTS1 receptor181-186.
Furthermore, D2Rs and NTS1 receptors have been shown to form heteromers in heterologous
expression systems, which resulted in a decrease in D2R agonist binding and decreases in D2R
signaling after treatment with neurotensin252,253. Previous research has shown that neurotensin
modifies midbrain DA neuron activity through two NTS1 receptor dependent mechanisms:
increased DA neuron firing through activation of a non-selective cation channel199-204 and a
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reduction in the inhibition of firing caused by D2R activation201,202,204,254-256. The majority of
evidence suggests that the effects of neurotensin on DA neurons occur through activation of
signaling pathways downstream of Gq-proteins, specifically through PKC, IP3, and
calcium201,203,257-259, although neurotensin has also been reported to affect DA neuron activity
through a PKA dependent mechanism256. In these studies we sought to examine the
mechanisms by which neurotensin reduces the D2R-mediated inhibition of DA neuron activity
by testing the hypothesis that neurotensin inhibits the D2R-mediated inhibitory post-synaptic
current (D2R IPSC)98 that occurs in response to the local, somatodendritic release of DA within
the VTA.

3.3

Materials and Methods
Animals: Male C57BL/6J male mice (5-12 weeks old) purchased from The Jackson

Laboratories were used in all experiments. All protocols and procedures were approved by the
Institutional Animal Care and Use Committee at Georgia State University, and conformed to the
NIH Guide for the Care and Use of Laboratory Animals.
Slice preparation and Electrophysiology: Acute brain slices were prepared as previously
described235. Briefly, adult male mice were anesthetized with isofluorane and decapitated. The
brain was then removed and placed in carbogen (95% O2 and 5% CO2) saturated ice-cold
artificial cerebral spinal fluid (aCSF), containing (in mM) 126 NaCl, 2.5 KCl, 2.4 CaCl2, 1.2
NaH2PO4, 1.2 MgCl2, 11.1 glucose, and 21.4 NaHCO3. A brain block containing the VTA was
made, and pseudo-horizontal sections (220 M) were cut with a vibrating blade microtome.
Slices were then incubated in aCSF (~35C) containing 10 M MK-801 [(+)-5-methyl-10, 11dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate] for at least 30 minutes before
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recording. Slices were placed in a recording chamber and perfused with carbogen-saturated
aCSF at a flow rate of ~ 1-2 ml/min. Whole-cell recordings were made using an Axon
multiclamp 700B microelectrode amplifier and Axograph software. Putative DA neurons were
identified by their location relative to the medial terminal nucleus of the accessory optic tract,
the presence of hyperpolarization-activated cation currents (H-current), the presence of
spontaneous pacemaker firing, and the sensitivity to DA237. Although recent studies have raised
questions on the utility of using these measures to identify VTA DA neurons29, the
characteristics described above have been widely used in electrophysiological studies on DA
neurons to identify DA neurons within the VTA98,235,254,258,260.
Electrodes (2.0-3.0 M) were filled with a potassium gluconate (KGluconate) based
internal solution containing (in mM) 128 KGluconate, 10 NaCl, 1 MgCl2, 10 HEPES, 10
BAPTA, 2 ATP, 0.3 GTP, and 10 creatine phosphate. For the experiments testing the effects of
neurotensin under reduced calcium buffering conditions, low-calcium buffering potassium
methyl sulfate (KMeSO4) or K-Gluconate based internal solutions were used containing: (in
mM) 115 KMeSO4, 20 NaCl, 1 MgCl2, 10 HEPES, 0.1 EGTA, 2 ATP, 0.3 GTP, and 10 creatine
phosphate, or (in mM) 128 KGluconate, 10 NaCl, 1 MgCl2, 10 HEPES, 0.1 EGTA, 2 ATP, 0.3
GTP, and 10 creatine phosphate. No differences were observed between these two low calcium
buffering internal solutions, so experiments using these two different internal solutions were
pooled. Series resistance values were approximately ~ 3-15 MΩ. If the series resistance
increased by more than 20% or if the IPSC or holding current were unstable in any of the
experiments, the experiment was terminated and excluded from analysis. Neurons were voltage
clamped at -60 mV for all experiments, and D2R IPSCs and GABAB IPSCs were evoked using
a bipolar stimulating electrode placed 100-300 M posterior to the recorded cell. D2R IPSCs
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were evoked with 5-stimuli (0.5 ms) at 40 Hz, and GABAB IPSCs were evoked with 6-stimuli
(0.3 ms) at 50 Hz. D2R IPSCs were also evoked using the iontophoretic application of DA.
DA was applied iontophoretically through a ~ 70-100 M glass pipette filled with 1 M DA and
ejected as a cation with a single pulse (10 nA, 25 ms). Leak of DA from the pipette was
prevented with a constant negative back current (2 nA). To isolate D2R IPSCs, picrotoxin (100
M), CGP 55845 (0.5 M), and DNQX (10 M) were included in the perfusion solution to
block GABAA, GABAB, and AMPA receptors, respectively. GABAB IPSCs were isolated by
including sulpiride (200 nM), picrotoxin (100 M), and DNQX (10 M) to block D2R,
GABAA, and AMPA receptors, respectively. The peak amplitude of all IPSCs was measured
from baseline and calculated as the mean current 30 ms before and after the peak IPSC
amplitude. For all experiments cells were held for 10 minutes prior to drug application to allow
for diffusion of the internal solution into the cell. For the experiments examining muscarinic
acetylcholine receptor induced currents, the nicotinic receptor antagonist, mecamylamine (30
M), was included both before and during application of acetylcholine. To determine the
voltage current relationship and reversal potential of the neurotensin current, voltage ramps
were applied (-120 mV to +40 mV at 160 mV s-1 or -120 mV to +20 mV at 140 mV s-1) in the
presence of TTX.
Drugs: The 8-13 active fragment of neurotensin (referred to as neurotensin) was used in
all experiments. Neurotensin (8-13) was purchased from Bachem Americas Inc. (Torrance, CA,
USA). CGP 55845, SKF 96365, cyclopiazonic acid, and DHPG were purchased from Tocris
Biosciences (Minneapolis, MN, USA). Chelerythrine was purchased from Sigma Aldrich (St.
Louis, MO, USA). Mecamylamine and acetylcholine were generous gifts from Dr. Chun
Jiang’s lab. All other reagents were from common commercial sources.
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Data Analysis and Statistics: Data are represented as the mean +/- SEM unless otherwise
noted. Data were analyzed using Axograph X (v1.3.5), LabChart (v7.3.6; ADInstruments), and
Excel (v14.0; Microsoft Corporation) software. Statistics were calculated using SigmaStat
(v11.0; Systat Software, Inc.). EC50 values were calculated using GraphPad Prism (v6.0f;
GraphPad Software, Inc.). Pearson’s correlation coefficient was used to calculate correlation.
All data were initially tested for normality using the Shapiro-Wilk test and were then analyzed
with Student’s t-tests, Mann-Whitney U tests, ANOVAs, or a Kruskal-Wallis One Way
ANOVA on ranks as appropriate with a significance level of p<0.05 set a priori.

3.4

Results
We initially examined how neurotensin affects DA neuron activity by assessing both the

inward current activated by neurotensin and its ability to affect the inhibitory current generated
by somatodendritic DA release in the VTA (D2R IPSC)98. Neurotensin dose-dependently
activated an inward current in DA neurons and inhibited the D2R IPSC (Fig. 3.1A-C).
Neurotensin also caused an increase in noise at all doses tested (Fig. 3.1C). The EC50 values of
the effects of neurotensin on VTA DA neurons were 208.7 nM for the inward current and 4.38
nM for the inhibition of the D2R IPSC (Fig. 3.1A-B). The inhibition of the D2R IPSC
positively correlated with the magnitude of the inward current (r=0.672, p=0.0006, Fig. 3.1D),
suggesting that neurotensin may activate the inward current and inhibit the D2R IPSC in VTA
DA neurons through a common mechanism.
The timing of the activation of the inward current and the inhibition of the D2R IPSC
differed however. The inward current caused by 100 nM neurotensin reached its peak quickly,
whereas the onset and peak of the inhibition of the D2R IPSC were delayed compared to the
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inward current (Fig. 3.2A-C). The washout and recovery of the effects of neurotensin also
differed as the neurotensin current and the increase in noise slowly reversed (in ~ 10-15
minutes), while the inhibition of the D2R IPSC never recovered during the drug washout period
(Fig. 3.2A,C). Furthermore, the D2R IPSC remained inhibited 10 minutes after neurotensin
application when the neurotensin current had almost completely recovered, suggesting that the
inward current is not simply occluding the D2R IPSC (Fig. 3.2A-C). Thus, although the
magnitude of the inward current correlated with the amount of inhibition of the D2R IPSC,
there were differences in the timing of the two effects of neurotensin, suggesting that they may
actually be mediated through different mechanisms.
We next sought to confirm whether the neurotensin caused inward current and inhibition
of the D2R IPSC were independent by inhibiting the inward current and measuring the effect of
neurotensin on the D2R ISPC. Thus, we attempted to confirm previous experiments identifying
the ion channels mediating the neurotensin-induced inward current in DA neurons. The
neurotensin-induced current obtained from slow voltage ramps showed a unique I-V
relationship with outward rectification and an extended zero slope region around the reversal
potential, which was calculated to be -36 +/- 6.6 mV (Fig. 3.3). This unique I-V curve,
combined with previous reports demonstrating that neurotensin activates a slow nonselective
cation conductance permeable to Na+, K+, and Cs+199,200,261, suggests that neurotensin may be
activating a member of the transient receptor potential C channel (TrpC) family262,263. Thus, we
tested whether SKF 96365, a TrpC channel blocker that was previously shown to block the
neurotensin caused increase in firing frequency in DA neurons203, could inhibit the neurotensininduced inward current in VTA DA neurons. SKF 96365 (100 M) partially inhibited the
neurotensin-induced inward current (Fig. 3.4C-D). Although the peak inward current caused by
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neurotensin (100 nM) was only slightly decreased by SKF 96365, the sustained neurotensininduced current rapidly decreased, and the duration of the neurotensin-induced inward current
was significantly shortened (Fig. 3.4C-D) (significant main effects of treatment (F(1, 9)=6.079,
p<0.05), and time (F(20, 175)=13.888, p<0.001), and a significant treatment×time interaction
(F(20,175)=2.583, p<0.001). In addition, the increase in noise caused by neurotensin also
partially recovered during the washout and recovery of the neurotensin-induced current. We
also tested whether SKF 96365 affected the ability of neurotensin to inhibit the D2R IPSC.
SKF 96365 had no effect on the ability of neurotensin to inhibit the D2R IPSC however, as the
peak inhibition of the D2R IPSC caused by neurotensin was unaffected (Fig. 3.4E-F). The D2R
IPSC also remained inhibited throughout the experiment even when the neurotensin current
recovered (Fig. 3.4A-B), suggesting that the inward current and the inhibition of the D2R IPSC
are likely independent and that the inward current caused by neurotensin does not simply
occlude the D2R IPSC.
We next sought to confirm that the effects of neurotensin on the D2R IPSC were
mediated post-synaptically and not through alterations in DA release, by testing whether
neurotensin also inhibited the D2R-mediated current generated by the iontophoretic application
of DA. As predicted, neurotensin inhibited the iontophoresis evoked D2R current (Fig. 3.5A) to
the same magnitude as the electrically evoked D2R IPSC (Fig. 3.5B-C). Thus, neurotensin
appears to act at the post-synaptic membrane to inhibit the D2R IPSC and not through a presynaptic change in DA release.
We next attempted to identify the mechanism by which neurotensin inhibits the D2R
IPSC. Previous studies suggested that neurotensin inhibits D2R signaling through a Ca2+ and
PKC dependent mechanism201,258,259. Therefore, we tested the role of the release of Ca2+ from
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intracellular stores in the neurotensin caused inhibition of the D2R IPSC through the use of the
reversible sarcoplasmic reticulum Ca2+ ATPase inhibitor, cycopiazonic acid (CPA).
Pretreatment of brain slices with CPA (10 M) for at least 15 minutes prior to neurotensin
application had no effect on the neurotensin (100 nM) inhibition of the D2R IPSC (Fig. 3.6AB). In addition, CPA had no effect on the peak inward current induced by neurotensin (Fig.
3.6C-D). We also tested whether neurotensin inhibits the D2R IPSC through a PKC-dependent
process through the use of the non-specific PKC inhibitor, chelerythrine. Chelerythrine (10
M) also had no effect on the neurotensin-induced inhibition of the D2R IPSC (Fig. 3.6A-B),
and there was no significant difference between the peak inward current induced by neurotensin
after chelerythrine treatment compared with neurotensin alone (Fig. 3.6C-D). Thus, in contrast
to previous reports201,258,259, the inhibition of the D2R IPSC in VTA DA neurons by neurotensin
does not appear to depend on PKC activation, nor does it depend on release of Ca2+ from
intracellular stores.
We next tested whether the inhibition of the D2R IPSC was specific to neurotensin or
could be achieved by activation of other Gq-coupled receptors by examining whether activation
of metabotropic glutamate receptors or muscarinic acetylcholine receptors also inhibited the
D2R IPSC. To activate muscarinic receptors, acetylcholine (ACh) was added in the presence of
mecamylamine (30 M), a nicotinic acetylcholine receptor antagonist. For this experiment, we
chose doses of the metabotropic glutamate receptor agonist, DHPG (10 M), ACh (1 mM), and
neurotensin (10 nM) that caused approximately the same peak inward current to allow for direct
comparison of their effects on the D2R IPSC (Fig. 3.7A-D). There were no significant
differences between the peak current activated by DHPG, ACh, and neurotensin
(F(2,16)=1.217, p=0.322) (Fig. 3.7D), but there were significant differences in the inhibition of
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the D2R IPSC, as neurotensin inhibited the D2R IPSC to a significantly greater extent than
DHPG or ACh (F(2,16)=5.181, p<0.05) (Fig. 3.7E). In addition, the effects of DHPG and ACh
on the D2R IPSC started to reverse upon removal of the agonist, whereas the effects of
neurotensin on the D2R IPSC showed no reversal (Fig. 3.7A-C). Thus, it appears that
activation of Gq-coupled receptors can inhibit the D2R IPSC, but activation of NTS1 appears to
engage an additional mechanism that causes significantly greater inhibition of the D2R IPSC.
We next sought to test whether the ability of neurotensin to inhibit the D2R IPSC was
specific to D2Rs or if it would also affect other inhibitory responses in VTA DA neurons.
GABAB receptors and D2Rs both inhibit VTA DA neurons through the activation of G-protein
coupled inward rectifying potassium channels (GIRK channels). Thus, we next tested whether
neurotensin also affected the IPSC generated by activation of GABAB receptors (GABAB IPSC)
(Fig. 3.8A-B). Interestingly, neurotensin inhibited the GABAB IPSC to a similar degree as the
D2R IPSC (Fig. 3.8C). This was true for both the maximal dose (100 nM) of neurotensin that
fully inhibited the D2R IPSC, and an intermediate dose (10 nM) closer to the EC50 value for
neurotensin inhibition of the D2R IPSC (Fig. 3.8C). Thus, neurotensin does not appear to
specifically inhibit the D2R IPSC in VTA DA neurons but can also inhibit the GABAB IPSC,
possibly through a common mechanism.
We next sought to examine the similarity of the inhibition of the D2R IPSC and the
GABAB IPSC in more detail. The D2R and GABAB IPSCs differ in their sensitivity to
intracellular Ca2+ levels as the D2R IPSC shows increased desensitization and long-term
depression when intracellular free Ca2+ levels are weakly buffered, whereas the GABAB IPSC is
insensitive to changes in intracellular Ca2+126. Thus, we next tested whether the effects of
neurotensin on the D2R and GABAB IPSCs were affected by basal intracellular Ca2+ levels by
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switching from a high Ca2+ buffering internal solution (containing 10 mM BAPTA = low levels
of basal free intracellular Ca2+) to a low Ca2+ buffering internal solution (containing 0.1 mM
EGTA = higher levels of basal free intracellular Ca2+). A dose of neurotensin near the EC50
value for inhibition of the D2R IPSC was used in these experiments to allow for the
identification of potential increases or decreases in the effect of neurotensin on the D2R and
GABAB IPSCs with the reduced calcium buffering internal solution. Neurotensin (10 nM) still
caused an inward current and slightly reduced both the D2R and GABAB IPSCs when measured
with a 0.1 mM EGTA internal solution (Fig. 3.9). Interestingly, the inward current induced by
neurotensin was significantly reduced compared to the inward current with the internal solution
containing 10 mM BAPTA (Fig. 3.9A-B) (significant main effects of treatment (F(1,
15)=23.357, p<0.001) and time (F(19,250=33.674, p<0.001), and significant treatment×time
interaction (F(19,250)=14.087, p<0.001). The neurotensin-caused inhibition of both the D2R
and GABAB IPSCs were also significantly reduced with the 0.1 mM EGTA internal solution
compared to the 10 mM BAPTA internal solution with no differences in the magnitude of
inhibition of the D2R IPSC versus the GABAB ISPC (Fig. 3.9C-F) (D2R IPSC: significant main
effects of treatment (F(1, 17)=32.102, p<0.001) and time (F(19, 288=33.157, p<0.001), and a
significant treatment×time interaction (F(19,288)=11.708, p<0.001); GABAB IPSC: significant
main effects of treatment (F(1,12)=17.439, p=0.001) and time (F(20, 240=18.321, p<0.001),
and a significant treatment×time interaction (F(20,240)=8.165, p<0.001). Thus, the effects of
neurotensin on DA neurons were greater when intracellular Ca2+ was strongly buffered and
resting levels of free intracellular Ca2+ were low, and were attenuated when intracellular Ca2+
was weakly buffered and resting levels of free intracellular Ca2+ were high.
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3.5

Discussion
In these studies we have demonstrated that neurotensin increases DA neuron activity

through multiple mechanisms. In addition to directly activating an inward current to increase
DA neuron activity, neurotensin also significantly reduced the inhibition of DA neurons caused
by activation of both D2R and GABAB receptors. These effects did not appear to depend on
release of Ca2+ from intracellular stores or on PKC activation, but were sensitive to basal levels
of free intracellular Ca2+.
The effects of neurotensin on the inward current and the D2R and GABAB IPSCs
appear to be independent and mediated by different mechanisms. The timing of neurotensin
inhibition of the D2R IPSC was significantly delayed compared to the inward current caused by
neurotensin, and the neurotensin-induced current recovered during the washout period after
neurotensin application, whereas the inhibition of the D2R IPSC did not. The EC50 values for
the two effects of neurotensin were also different, further supporting the argument that the two
effects of neurotensin occur through separate mechanisms. The EC50 value for inhibition of the
D2R IPSC by neurotensin was ~ 4 nM, much lower than the EC50 value for the neurotensin
induced current (~ 200 nM), and lower doses of neurotensin (1-10 nM) have often been used
previously to examine the effect of neurotensin on D2R signaling201,202,204,254-256 while higher
doses of neurotensin (1 nM to 5 M) have been used to examine the neurotensin induced inward
current in DA neurons199-204. In addition, partially inhibiting the neurotensin current with SKF
96365 did not have any effect on the neurotensin caused inhibition of the D2R IPSC. Finally,
ACh, DHPG, and neurotensin caused inward currents that were similar in magnitude, but
neurotensin had a much larger effect on the D2R IPSC. If the inward current caused the
inhibition of the D2R IPSC, then it would be expected that neurotensin, ACh, and DHPG would
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inhibit the D2R IPSC to the same magnitude when activating inward currents of the same size.
In agreement with our findings, it was previously reported that neurotensin reduces quinpirole
(D2R agonist) induced inhibition of DA activity even when the excitatory effect of neurotensin
is blocked with heparin, an IP3 receptor antagonist201. Therefore, it appears that the neurotensin
inward current does not block the D2R IPSC because of occlusion or net excitation, and that
these are independent effects downstream of NTS1 activation.
The neurotensin-induced inward current has been characterized as a slow non-selective
cation current that is equally permeable to both Na+ and K+, a characteristic of Trp channels199.
The neurotensin-induced current in DA neurons was similar to that generated by activation of
specific TrpC channels expressed in HEK-293 cells262,263 suggesting that neurotensin may be
activating a member of the TrpC family, potentially through the activation of phospholipase C
and release of DAG264,265. We found that the TrpC channel blocker SKF 96365 significantly
shortened the duration of the neurotensin-induced current, which is in agreement with a
previous report showing that SKF 96365 blocks the neurotensin-caused increase in DA neuron
firing frequency203. Thus, it appears that the neurotensin activated inward current is at least
partially mediated by activation of TrpC channels in VTA DA neurons.
The majority of evidence suggests that the effects of neurotensin on DA neurons are
mediated by signals that are downstream of PLC activation. Previously it was reported that the
neurotensin-induced inward current and increase in firing frequency are dependent on Ca2+ and
the IP3 receptor201,203,257. Another study found that the neurotensin-induced inward current was
not dependent on Ca2+, however, as the neurotensin current was not affected by buffering
intracellular Ca2+ with 20 mM BAPTA199. In addition it has also been reported that neurotensin
inhibits D2R signaling through a PKC and Ca2+ dependent mechanism201,258,259. In contrast to

37

these previous reports, we found that the neurotensin inhibition of the D2R IPSC and the
neurotensin-induced current were not dependent on PKC or Ca2+, and the effects of neurotensin
were actually potentiated when intracellular Ca2+ was buffered with 10 mM BAPTA. In
addition, the neurotensin inhibition of the D2R IPSC and the inward current were not dependent
on Ca2+ release from intracellular stores. Interestingly, it has also been reported that
neurotensin reduces the DA-caused inhibition of DA neuronal firing through the cAMP
pathway and not through a PKC dependent mechanism256. Additional experiments are needed
to resolve these differences, however, and to determine if the effects of neurotensin occur
through dual pathways.
Although neurotensin likely inhibits the D2R IPSC via activation of Gq coupled
signaling through a mechanism similar to metabotropic glutamate receptors and muscarinic
acetylcholine receptors, here we have shown that there appears to be an additional mechanism
activated by neurotensin to inhibit the D2R IPSC to a larger extent than other Gq coupled
receptors. Interestingly, we also found that the effects of neurotensin were not specific to the
D2R IPSC as neurotensin also inhibited the GABAB IPSC to the same magnitude. This
suggests that the effects of neurotensin are likely not due to modulation of D2R activity by
direct heterodimer interactions with NTS1 as has been observed in HEK-293 cells252,253.
Previously it was reported that neurotensin does not block GABA caused inhibition of DA
neuronal firing202. GABA inhibits DA neurons through the activation of both GABAA and
GABAB receptors, however, so neurotensin may only block the inhibition produced by GABAB
receptors and not GABAA receptors, which could explain the differences in these results. Thus
the results presented here suggest that neurotensin inhibits both GABAB and D2R signaling in
VTA DA neurons.
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In these studies, we have shown a novel mechanism for modulation of VTA DA neuron
activity by neurotensin: inhibition of GABAB IPSCs. GABAB receptors and D2Rs both activate
GIRK channels to inhibit DA neurons, so it is possible that neurotensin modulates GIRK
channel activity downstream of both D2R and GABAB activation to reduce D2R and GABAB
caused inhibition of DA neurons (Fig. 3.10). In support of this notion, it was previously shown
that neurotensin blocks D2R signaling downstream of the D2R266. In addition, it was recently
reported that inducing high frequency bursting or depolarization in VTA DA neurons causes
potentiation of GIRK currents and this potentiation was due to modulation to the GIRK
channels themselves rather than regulation of the GABAB or D2 receptors127. Thus, neurotensin
may reduce both D2R and GABAB mediated GIRK currents by causing direct modulation of
GIRK channels, although further experiments will be required to test this hypothesis.
D2R IPSC desensitization and long-term depression have been reported to increase
when intracellular Ca2+ is weakly buffered and free intracellular Ca2+ levels are high, whereas
GABAB IPSCs do not show the same sensitivity to intracellular Ca2+ levels126. Combined with
the ability of neurotensin to increase Ca2+ in DA neurons201,203, these results suggest that
reducing the Ca2+ buffering capacity of the internal solution would result in a larger effect of
neurotensin on the D2R IPSC but not the GABAB IPSC. Surprisingly, the neurotensin-caused
inhibition of both the GABAB and D2R IPSCs were significantly attenuated with low
intracellular Ca2+ buffering (i.e. 0.1 mM EGTA solution). Thus, neurotensin appears to inhibit
GIRK current activation downstream of D2R and GABAB receptors through a Ca2+ sensitive
mechanism, whereby low levels of free intracellular calcium are required for the full inhibition
of GIRK channel activation (Fig. 3.10). Alternatively, it is also possible that the NTS1 receptor
is Ca2+ sensitive. We found that the neurotensin-induced inward current was also significantly
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reduced with low intracellular Ca2+ buffering. Thus, all effects of neurotensin in DA neurons
were reduced with low intracellular Ca2+ buffering and high intracellular levels of free Ca2+.
Therefore, it is possible that the NTS1 receptor may be sensitive to free intracellular Ca2+ levels
and may desensitize or internalize with high levels of free intracellular Ca2+ resulting in a
reduced effect of neurotensin, although future studies will be required to test this hypothesis.
In summary, we have demonstrated that neurotensin affects DA neuron activity through
two seemingly independent effects: direct activation of an inward current mediated in part by
TrpC channels, and inhibition of both the D2R and GABAB IPSCs. Overall these studies
advance our understanding of how neurotensin regulates DA neuron activity, and further
research characterizing how neurotensin affects DA neuron activity may lead to a better
understanding and treatments of disorders caused by a disruption in the function of the
mesolimbic DA system.
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3.6

Figures

Figure 3.1: Neurotensin dose-dependently activates an inward current and inhibits the D2R
IPSC in VTA DA neurons.
A. Dose-response curve of the inward current induced by neurotensin. B. Dose-response curve
of the inhibitory effect of neurotensin on the D2R IPSC. C. Sample traces of the neurotensin
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(NT) induced current (left) and inhibition of the D2R IPSC (right). D. The size of the inward
current is positively correlated to the amount of inhibition of the D2R IPSC. Bars in C indicate
time of neurotensin application. n=5-7 cells from 4-7 mice for each dose. Scale Bars: 50 pA/2
min (1 nM NT current); 100 pA/2 min (10 nM NT current); 200 pA/2 min (100 nM NT
current); 20 pA/500 ms (NT inhibition of D2R IPSC).

Figure 3.2: The neurotensin-induced inward current preceeds the inhibition of the D2R IPSC.
A. Sample cell of the effects of neurotensin (100 nM) on the inward current and the D2R IPSC.
B. Sample traces of the D2R IPSCs in A before neurotensin (a; black trace), during the peak of
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the neurotensin inward current (b; grey trace), and at 8-10 minutes after neurotensin washout (c;
grey trace). C. Mean responses of the effects of neurotensin (100 nM) on the inward current
and the D2R IPSC. Bars in A and C indicate time of neurotensin application. n=6 cells from 6
mice. Scale Bars: 20 pA/500 ms

Figure 3.3: Current -Voltage relationship of the neurotensin-induced current in VTA DA
neurons.
A. Sample current traces resulting from slow voltage ramps (-120 mV to +20 mV at 140 mV s-1)
before (black trace) and after neurotensin (100 nM; grey trace). B. Sample trace of the net
neurotensin (100 nM) induced current. C. Mean current-voltage relationship of the neurotensin
(100 nM) induced current. n=7 neurons from 4 mice. Scale Bars: 1 nA/200 ms
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Figure 3.4: The TrpC channel inhibitor, SKF 96365, partially blocks the neurotensin-induced
inward current but does not affect the inhibition of the D2R IPSC.
A. Sample cell of the effects of neurotensin (100 nM) on the inward current and the D2R IPSC
in the presence of SKF 96365 (100 M). Inset: sample trace of the D2R IPSC before
neurotensin (a; black trace) and 8-10 minutes after neurotensin washout (b; grey trace) in the
presence of SKF 96365. B. Mean responses of the effects of neurotensin (100 nM) on the
inward current and the D2R IPSC in the presence of SKF 96365 (100 M). C. Mean inward
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current generated by neurotensin (100 nM) in the absence and presence of SKF 96365 (100
M). D. Mean neurotensin-induced current at the peak and 5 minutes after neurotensin washout
in the presence and absence of SKF 96365. E-F. Mean effect of neurotensin (100 nM) on the
D2R IPSC in the absence and presence of SKF 96365 (100 M). Bars in A-C and E indicate
time of neurotensin and SKF 96365 application. n=5-6 neurons from 4-6 mice for each group.
Scale bar: 20 pA/500 ms. *p<0.05 vs. neurotensin alone

Figure 3.5: Neurotensin inhibits the D2R-mediated current produced by DA iontophoresis.
A. Sample trace of the effect of neurotensin (100 nM) on the D2R-mediated current produced
by DA iontophoresis. B-C. Mean effect of neurotensin (100 nM) on the D2R-mediated current
produced by DA iontophoresis and on the D2R IPSC evoked with electrical stimulation. Bar in
B indicates time of neurotensin application. n=6 neurons from 5-6 mice for each group. Scale
Bar: 20 pA/500 ms. *p<0.05
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Figure 3.6: Neurotensin inhibition of the D2R IPSC and the neurotensin-induced current are
not dependent on PKC activity or release of Ca2+ from intracellular stores.
A-B. Mean inhibition of the D2R IPSC caused by neurotensin (100 nM) in the presence and
absence of CPA (10 M) or chelerythrine (CHE) (10 M). C-D. Mean neurotensin (100 nM)
induced current in the presence and absence of CPA (10 M) or CHE (10 M). Bars in A and
C indicate time of neurotensin application. n=5-6 cells, from 4-6 mice for each group.
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Figure 3.7: Neurotensin inhibits the D2R IPSC significantly more than DHPG or acetylcholine.
A. Mean inward current and inhibition of the D2R IPSC caused by DHPG (10 M). Inset:
Sample trace of the D2R IPSC before DHPG (a; black trace) and at 7-11 minutes after applying
DHPG (b; grey trace). B. Mean inward current and inhibition of the D2R IPSC caused by ACh
(1 mM) in the presence of mecamylamine (30 M). Inset: Sample trace of the D2R IPSC before
ACh (a; black trace) and at 7-11 minutes after applying ACh (b; grey trace). C. Mean inward
current and inhibition of the D2R IPSC caused by neurotensin (10 nM). Inset: Sample trace of
the D2R IPSC before neurotensin (a; black trace) and at 7-11 minutes after applying neurotensin
(b; grey trace). D. The peak inward currents caused by DHPG (10 M), ACh (1 mM), and
neurotensin (10 nM) were not significantly different. E. Neurotensin (10 nM) inhibited the D2R
IPSC significantly more than DHPG and ACh. Bars in A-C indicate time of drug application.
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DHPG: n=5 cells from 4 mice; ACh: n=8 cells from 7 mice; neurotensin: n=6 cells from 5 mice.
Scale bars: 30 pA/500 ms. *p<0.05 vs. neurotensin

Figure 3.8: Neurotensin inhibits the GABAB IPSC in VTA DA neurons.
A-B. Sample traces (A) and mean effect (B) of neurotensin (100 nM & 10 nM; grey trace) on
the GABAB IPSC. C. Neurotensin (100 nM & 10 nM) inhibited the GABAB and D2R IPSCs by
the same magnitude. Bar in B indicates time of NT application. n=5-8 cells from 4-6 mice for
each group. Scale Bars: 20 pA/300 ms.
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Figure 3.9: Reduced buffering of intracellular calcium attenuates the effects of neurotensin.
A-B. Mean neurotensin (10 nM) induced inward current with an internal solution containing 10
mM BAPTA or 0.1 mM EGTA. C-F. Sample traces (C,E) and mean effect (D,F) of neurotensin
(10 nM; grey trace) on the D2R IPSC (C-D) and GABAB IPSC (E-F) using internal solutions
containing 10 mM BAPTA or 0.1 mM EGTA. Bars in A, D, & F indicate time of neurotensin
application. n=5-12 cells from 4-11 mice for each group. Scale Bars: 20 pA/400 ms (C); 20
pA/200 ms (D). #p<0.05, *p0.001
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Figure 3.10: Diagram of the proposed model of neurotensin inhibition of GIRK currents
activated by D2 and GABAB receptors.
Activation of NTS1 with neurotensin in VTA DA neurons causes robust inhibition of D2R and
GABAB GIRK currents when the relative levels of free intracellular Ca2+ are low due to strong
Ca2+ buffering, while neurotensin induced inhibition of D2R and GABAB GIRK currents is
significantly attenuated when relative levels of free intracellular Ca2+ are higher due to weak
Ca2+ buffering.
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Adapted from:
K.S. West, A.G. Roseberry (2017) Neuropeptide-Y alters VTA dopamine neuron activity
through both pre- and postsynaptic mechanisms. Journal of Neurophysiology, 118(1): 625-33
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4

NEUROPEPTIDE-Y ALTERS VTA DOPAMINE NEURON ACTIVITY THROUGH
BOTH PRE- AND POST-SYNAPTIC MECHANISMS

4.1

Abstract
The mesocorticolimbic dopamine system, the brain’s reward system, regulates many

different behaviors including food intake, food reward, and feeding related behaviors, and there
is increasing evidence that hypothalamic feeding-related neuropeptides alter dopamine neuron
activity to affect feeding. For example, neuropeptide-Y (NPY), a strong orexigenic
hypothalamic neuropeptide, increases motivation for food when injected into the ventral
tegmental area (VTA). How NPY affects the activity of VTA dopamine neurons to regulate
feeding behavior is unknown, however. In these studies we have used whole cell patch-clamp
electrophysiology in acute brain slices from mice to examine how NPY affects VTA dopamine
neuron activity. NPY activated an outward current that exhibited characteristics of a G proteincoupled inwardly rectifying potassium (GIRK) channel current in approximately sixty percent
of dopamine neurons tested. In addition to its direct effects on VTA dopamine neurons, NPY
also decreased the amplitude and increased paired-pulse ratios of evoked excitatory postsynaptic currents (EPSCs) in a subset of dopamine neurons, suggesting that NPY decreases
glutamatergic transmission through a pre-synaptic mechanism. Interestingly, NPY also strongly
inhibited evoked inhibitory post-synaptic currents (IPSCs) onto dopamine neurons by a presynaptic mechanism. Overall these studies demonstrate that NPY utilizes multiple mechanisms
to affect VTA dopamine neuron activity, and they provide an important advancement in our
understanding of how NPY acts in the VTA to control feeding behavior.
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4.2

Introduction
Over one third of the U.S. adult population is obese9,267, putting these individuals at

increased risk for numerous other deleterious conditions, including diabetes, cardiovascular
disease, stroke, high blood pressure, and some forms of cancer268. As there are currently few
effective treatments available to combat obesity269, it is essential to understand how the brain
controls feeding and weight gain in order to identify new targets that can be used to develop
effective treatments for obesity and weight gain.
The mesocorticolimbic dopamine system is the primary neural circuit regulating rewardrelated and motivational behaviors, and this system plays an important role in controlling
feeding and body weight, including the appetitive and consummatory aspects of
feeding12,15,163,164,270,271. For example, dopamine deficient mice are aphagic and will starve to
death by 4 weeks of age if they are not treated with L-DOPA, a dopamine precursor133. Food
intake, food reward, and stimuli associated with food also cause phasic increases in dopamine
release136,137,272, and blocking dopamine receptors systemically or in the nucleus accumbens
decreases operant responding for food in rats132,273,274. Impairments in the mesocorticolimbic
dopamine system have also been associated with obesity and dysregulated feeding in humans.
For example, dopamine agonists cause increased compulsive eating and weight gain in
Parkinson’s patients141, and obese individuals show increased activity in mesocorticolimbic
areas in response to pictures of palatable food but decreased responses to food consumption
compared to lean individuals144-147,275. Overall we have an incomplete understanding of how the
mesocorticolimbic dopamine system regulates feeding, however. This includes an incomplete
understanding of how other brain systems and circuits interact with dopamine circuits to
regulate feeding and body weight.
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Neuropeptide-Y (NPY) is a strong orexigenic neuropeptide and an important regulator
of energy homeostasis276,277. For example, central administration of NPY robustly increases
food intake212,213, activation of NPY expressing neurons in the arcuate nucleus of the
hypothalamus increases feeding211, and ablation of NPY neurons reduces food intake and body
weight214,215. There is also evidence that NPY interacts with the mesocorticolimbic dopamine
system to regulate feeding. NPY neurons project to the VTA278, NPY receptors are expressed
in the VTA217,279,280, and intra-VTA and intra-nucleus accumbens injection of NPY increases
operant responding for food in rats174. There is conflicting data on exactly how NPY acts in the
VTA to affect feeding, however. Intra-cerebroventricular (icv) NPY has been shown to increase
dopamine efflux in the nucleus accumbens suggesting that NPY may activate dopamine
neurons281-283, but a separate study has shown that NPY decreases the firing rate of VTA
dopamine neurons in ex vivo brain slice preparations217. Thus, overall, it is unknown how NPY
affects VTA dopamine neurons to regulate feeding. Therefore, in these studies we have used
patch-clamp electrophysiology in acute brain slice preparations to test whether NPY inhibits
VTA dopamine neurons through direct action on dopamine neurons or through the pre-synaptic
regulation of their synaptic inputs.

4.3

Materials and Methods
Animals: Male and female mice (5-14 weeks old) on a C57Bl/6J or a mixed C57/129

background were used in all experiments. All protocols and procedures were approved by the
Institutional Animal Care and Use Committee at Georgia State University, and conformed to the
NIH Guide for the Care and Use of Laboratory Animals.
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Slice preparation and Electrophysiology: Acute brain slices were prepared as previously
described234,235. Briefly, adult mice were anesthetized with isofluorane and decapitated. The
brain was then removed and placed in carbogen (95% O2 and 5% CO2) saturated ice-cold
artificial cerebral spinal fluid (aCSF), containing (in mM) 126 NaCl, 2.5 KCl, 2.4 CaCl2, 1.2
NaH2PO4, 1.2 MgCl2, 11.1 glucose, and 21.4 NaHCO3. A brain block containing the VTA was
made, and pseudo-horizontal sections (220 m) were cut with a vibrating blade microtome.
Slices were then incubated in aCSF (~35C) containing 10 M MK-801 [(+)-5-methyl-10, 11dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate] for 30-60 min before recording.
Slices were placed in a recording chamber and perfused with carbogen-saturated aCSF at a flow
rate of approximately 1-2 ml/min. Whole-cell recordings were made using an Axon multiclamp
700B microelectrode amplifier and Axograph software. Putative dopamine neurons were
identified by their location relative to the medial terminal nucleus of the accessory optic tract,
the presence of hyperpolarization-activated cation currents (H-current), and the presence of
spontaneous pacemaker firing237.
Electrodes (2.0-3.0 M) were filled with a potassium gluconate (KGluconate) based
internal solution containing (in mM) 128 KGluconate, 10 NaCl, 1 MgCl2, 10 HEPES, 2 ATP,
0.3 GTP, 10 creatine phosphate, and 10 BAPTA or 0.1 EGTA. The internal solution contained
EGTA for the experiments examining the direct effect of NPY on dopamine neuron activity
under reduced calcium buffering conditions and for the experiments examining the effect of
NPY on excitatory post-synaptic currents (EPSC). The internal solution contained BAPTA for
all other experiments, with the exception of the measurement of inhibitory post-synaptic
currents (IPSC), where a potassium methylsulfate based internal solution containing a high
concentration of Cl- was used (in mM) 57 KCl, 70 KMeSO4, 20 NaCl, 1.5 MgCl2, 5 HEPES, 0.1
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EGTA, 2 ATP, 0.3 GTP, and 10 creatine phosphate. Series resistance values were
approximately 3-15 M. If the series resistance increased by more than 20% the experiment
was terminated or excluded from analysis. In addition, if the holding current changed by more
than 10 pA during baseline recording or during the first minute of NPY application the
experiment was terminated or excluded from analysis. Neurons were voltage clamped at -60
mV for most experiments. Corrections were not made for the liquid junction potential, which
was calculated to be the following for each internal: KGluconate 10 mM BAPTA, 13.9 (normal
aCSF), 13.6 (high K+ external solution); KGluconate 0.1 mM EGTA, 14.8; K
methylsulfate/KCL, 6. EPSCs/IPSCs were evoked using a bipolar stimulating electrode placed
100-300 m from the recorded cell. The electrode was placed anterior to the recorded cell to
evoke EPSCs and posterior to the recorded cell to evoke IPSCs. Pairs of PSCs were evoked
with a 50 ms interpulse interval every 20 s. EPSCs were isolated by including picrotoxin (100
M) in the perfusion solution, and IPSCs were isolated by including DNQX (10 M) in the
perfusion solution. For all experiments, cells were held for at least 10 minutes prior to drug
application to allow for diffusion of the internal solution into the cell. To determine the currentvoltage relationship and the reversal potential of the NPY current, cells were perfused with a
high K+ external solution containing TTX: (in mM) 118.5 NaCl, 10 KCl, 2.4 CaCl2, 1.2
NaH2PO4, 1.2 MgCl2, 11.1 glucose, 21.4 NaHCO3, and 0.001 TTX. The cells were then held at
-40 mV and slow voltage ramps were applied from -100 mV to 0 mV at 100 mV s-1 every 30 s.
Drugs: Neuropeptide-Y and BIBP3226 were purchased from Bachem (Torrance, CA).
TTX was purchased from Tocris Biosciences (Minneapolis, MN). All other reagents were from
common commercial sources.
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Data Analysis and Statistics: Data are represented as the mean +/- SEM unless otherwise
noted. For all PSC measurements, the effect of NPY on EPSCs/IPSCs was determined by
comparing the average value of the PSCs measured 5 min before the onset of NPY to the
average values 5 min after the onset of NPY treatment. The pair-pulse ratio was calculated by
dividing the amplitude of the second PSC by the amplitude of the first PSC. The coefficient of
variation was calculated by dividing the SD by the mean of the PSC amplitude. Data were
analyzed using Axograph X (v1.3.5), LabChart (v7.3.6; ADInstruments), and Excel (v14.0;
Microsoft Corporation) software. Statistics were calculated using SigmaStat (v11.0; Systat
Software, Inc.). Data were initially tested for normality using the Shapiro-Wilk test and were
then analyzed with Student’s t-tests, Wilcoxon signed-rank tests, or a two-way ANOVA with
Holm-Sidek post-hoc tests as appropriate with a significance level of p<0.05 set a priori. For
the experiments comparing the responses to NPY and baclofen with the BAPTA and EGTA
internal solutions (Fig. 4.4), the data was log transformed to achieve normality prior to running
a two-way ANOVA.

4.4

Results
There is conflicting data on whether NPY increases or decreases VTA dopamine neuron

activity217,281-283. Thus, we used patch-clamp electrophysiology in acute brain slice preparations
to test whether NPY directly regulates VTA dopamine neuron activity. NPY activated an
outward current in approximately 58% of VTA dopamine neurons tested (Fig. 4.1A-C; 37 out of
64 neurons total; 10 nM= 6 of 12; 100 nM= 27 of 42; 300 nM 4 of 10). The NPY activated
current was concentration-dependent (Fig. 4.1A-C) and was accompanied by a significant
decrease in membrane resistance (Fig. 4.1D-E), suggesting that NPY directly activates an ionic
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conductance in VTA dopamine neurons. Thus, it appears that NPY directly inhibits VTA
dopamine neurons. The 100 nM and 300 nM concentrations of NPY were used in all
subsequent experiments, as both appeared to be saturating concentrations.
We next sought to identify the NPY receptor mediating the NPY-induced current in
VTA dopamine neurons. Previous studies have reported that the post-synaptic effects of NPY
are mediated by NPY acting on Y1 and Y2 receptors284-289. We initially tested whether Y1
receptors (Y1R) mediated this effect using the Y1R antagonist, BIBP3226284-289. BIBP3226 (1
µM) reversed the NPY-induced current when it was applied at the peak of the NPY current (Fig.
4.2A-C, n=4, note the rate of reversal of the NPY-induced current with BIBP3226 compared to
NPY alone in Fig. 4.1A-B). In addition, pretreatment with BIBP3226 (1 µM) completely
prevented the NPY induced current in all cells tested (Fig. 4.2D-E, n=8). Thus NPY appears to
directly inhibit VTA dopamine neurons by activating Y1Rs.
We next sought to determine the identity of the channel mediating the NPY activated
current in VTA dopamine neurons. We tested the current-voltage relationship of the NPY
current by applying slow voltage ramps (-100 mV to 0 mV 100 mV s-1) in a high K+ (10 mM)
external solution containing TTX (1 M). The current obtained from these slow voltage ramps
exhibited inward rectification and had a reversal potential near that of the reversal potential for
potassium ions under these conditions (Fig. 4.3A-C; EK= -68 mV; NPY Erev= -59.6 mV +/- 8.8
mV). These results indicated that NPY induced a potassium current in VTA dopamine neurons
that is likely mediated by activation of GIRK channels. We then tested whether extracellular
barium (1 mM) could inhibit the NPY induced current (Fig. 4.3A, D-E). Barium is a known
blocker of inwardly rectifying potassium channels, including GIRK channels290,291, and it has
been shown to block NPY-induced GIRK currents in many different CNS neurons284-289.
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Extracellular barium reversed and blocked the NPY current along with a basal leak current in
VTA dopamine neurons (Fig. 4.3A, D-E). Thus, it appears that NPY activated GIRK channels
in VTA dopamine neurons.
We next tested whether the NPY activated current in VTA dopamine neurons was
sensitive to intracellular calcium levels, because previous studies have shown that GIRK
currents are smaller when intracellular calcium buffering is reduced in VTA dopamine
neurons126,260. As a positive control, we also tested whether GIRK currents activated by the
GABAB receptor agonist, baclofen (1 M), were dependent on the strength of intracellular
calcium buffering. The NPY-induced currents were significantly smaller than the baclofeninduced currents (Fig. 4.4), and, as expected, both NPY (100 nM) and baclofen (1 M) currents
were significantly smaller with reduced intracellular calcium buffering (0.1 mM EGTA)
compared to strong calcium buffering (10 mM BAPTA) (Fig. 4.4; significant main effects of
drug (F(1, 23)=7.807, p=0.010) and calcium buffering (F(1, 23)=19.165, p<0.001)),
demonstrating that intracellular calcium regulates GABAB- and NPY-induced currents in a
similar manner. Thus, these results further suggest that NPY activates a GIRK channel current
in VTA dopamine neurons and demonstrate that this current is sensitive to intracellular calcium
levels.
In addition to directly inhibiting VTA dopamine neurons, it is possible that NPY could
regulate the activity of dopamine neurons indirectly through modulation of their afferent inputs.
Glutamatergic and GABAergic afferent inputs are important regulators of dopamine neuron
activity58,66,69, and NPY has been shown to affect glutamatergic and GABAergic transmission in
other areas of the CNS284,285,289,292. Thus, we next examined whether NPY altered glutamatergic
inputs to dopamine neurons. NPY decreased the amplitude of evoked EPSCs in 7 of the 10
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VTA dopamine neurons tested (Fig. 4.5A-E, range of effect = 68% - 91% of baseline). In order
to examine the mechanism by which NPY decreased EPSCs, we assessed whether there were
changes to the paired-pulse ratio (PPR) and coefficient of variation (CV) of the EPSCs after
treatment with NPY. PPR and CV are measures used to determine whether a change in synaptic
strength is due to a pre-synaptic or post-synaptic modification, and PPR and CV values have
been shown to significantly increase when the probability of pre-synaptic neurotransmitter
release is decreased but do not change when the amplitude of PSCs are affected by a postsynaptic modification293,294. NPY (100 nM) significantly increased both the PPR and CV of the
EPSCs inhibited by NPY (Fig. 4.5D,F,H,J; n=7 of 10) without affecting the PPR or CV of the
EPSCs whose amplitude was not affected by NPY (Fig. 4.5E,G,I,K; n=3 of 10). Thus, it
appears that NPY decreased glutamatergic transmission onto a subset of VTA dopamine
neurons through an inhibition of presynaptic release. We next examined whether the NPYinduced current and the inhibition of EPSCs were related effects by assessing whether NPY
activated GIRK currents and inhibited EPSCs in the same neurons or in distinct populations of
VTA dopamine neurons. NPY inhibited EPSCs in both dopamine neurons that showed an
NPY-induced outward current (n=3 of 10) and in neurons that did not directly respond to NPY
(n=4 of 10), and the magnitude of the inhibition of the EPSCs was similar for both sets of
neurons (Fig. 4.5L-M). These results suggest that NPY inhibited EPSCs independent of the
NPY induced GIRK current, and that NPY inhibits EPSCs and activates inhibitory GIRK
currents in both distinct and overlapping sets of VTA dopamine neurons.
NPY has also been reported to inhibit VTA GABA neurons217, which provide important
inhibitory input to VTA dopamine neurons21,58,66,69. Therefore, we next tested whether NPY
also altered GABAergic inputs to VTA dopamine neurons. NPY strongly inhibited evoked
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IPSCs in 4 out of 6 dopamine neurons tested (Fig. 4.6A-C; range of effect = 30% - 85% of
baseline), and increased the PPR and CV of the affected IPSCs (Fig. 4.6C-F; n=4 of 6),
although the CV did not reach statistical significance. NPY did not decrease evoked IPSCs in 2
out of 6 dopamine neurons tested but did activate GIRK currents in both of these neurons,
suggesting that, as with NPY’s effect on EPSCs, the inhibition of the IPSCs is not related to the
NPY-induced GIRK current. Thus, NPY appears to also decrease GABAergic transmission
onto a subset of VTA dopamine neurons through an inhibition of presynaptic release.

4.5

Discussion
In these studies we have used patch-clamp electrophysiology in acute brain slice

preparations to determine how NPY alters VTA dopamine neuron activity to affect feeding.
NPY inhibited a subset of dopamine neurons through two mechanisms: NPY directly inhibited
dopamine neurons through Y1R mediated activation of GIRK channels, and NPY indirectly
inhibited dopamine neurons by decreasing glutamatergic transmission onto dopamine neurons.
Interestingly, NPY also decreased GABAergic transmission onto a subset of dopamine neurons,
indicating that NPY could cause excitation of some VTA dopamine neurons.
A previous study found that NPY decreases the firing rate of a subset of VTA dopamine
neurons in ex vivo brain slices from rats217, but the mechanism of this NPY caused inhibition of
dopamine neurons was unknown. NPY mediates its effects through five known receptors, Y1,
Y2, Y4, Y5, and Y6295,296. All of the NPY receptors are G protein-coupled receptors that signal
through Gi/o G-proteins295,296, and NPY causes a GIRK channel current in neurons located in
different areas of the CNS284-289. Thus, we hypothesized that NPY inhibited dopamine neurons
through a similar mechanism. Indeed, the results presented here support the hypothesis that
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NPY activates GIRK channels in VTA dopamine neurons as NPY caused a concentration
dependent outward current that was accompanied by a decrease in membrane resistance,
reversed at the reversal potential for K+ ions, exhibited inward rectification, and was sensitive to
extracellular barium, which is similar to what has been reported in numerous other brain
regions284-289. Thus, we can conclude that NPY activates Y1Rs that in turn release activated
Gi/o-proteins to open GIRK channels.
The NPY-induced current was also sensitive to intracellular calcium levels, which is an
interesting characteristic of GIRK currents in VTA dopamine neurons126,260. For example,
GIRK currents activated by GABAB and dopamine D2 receptor agonists are reported to be
smaller when intracellular calcium buffering is reduced and calcium levels are high in VTA
dopamine neurons126,260. We found that, like the baclofen-induced currents, the NPY-induced
currents were significantly smaller under reduced calcium buffering conditions. One potential
caveat in these experiments is that the NPY currents could have affected the amplitude of the
subsequent baclofen currents through heterologous desensitization, although this would not
affect the interpretation of these results, as we would expect this to be true for both low and
high calcium buffering. Thus, taken together, our findings indicate that NPY directly inhibits
VTA dopamine neurons by activating a GIRK current that is sensitive to intracellular calcium
levels.
In addition to the direct effects of NPY on VTA dopamine neurons, we also examined
whether NPY indirectly affected dopamine neuron activity through modulation of their
glutamatergic and GABAergic afferent inputs, which play an important role in controlling
dopamine neuron activity58,66,69. Glutamatergic afferents primarily control dopamine neuron
burst firing, and GABAergic afferents strongly inhibit dopamine neurons, demonstrating that
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these afferent inputs are important regulators of dopamine neuron activity58,66,69. Surprisingly,
NPY decreased both excitatory glutamatergic and inhibitory GABAergic transmission onto
VTA dopamine neurons, although not to the same extent (Fig. 4.5-6). NPY decreased both
glutamatergic and GABAergic transmission through a decrease in pre-synaptic release, which is
similar to what has been reported in other areas of the CNS284,285,289. Thus, NPY modulates
VTA dopamine neuron activity through two different pre-synaptic mechanisms.
The net effect of NPY on the overall activity of VTA dopamine neurons is unclear,
because the responses observed here would result in both activation and inhibition of dopamine
neurons. The inhibitory effects of NPY on VTA dopamine neurons were relatively small (a
small (~ 50 pA) direct inhibition, and a modest ~ 18% decrease in EPSCs), whereas the
excitatory effect of NPY was more robust (~ 44% decrease in IPSCs), suggesting that NPY
could have a net excitatory effect on VTA dopamine neuron activity. This possibility is
supported by previous studies suggesting that NPY excites VTA dopamine neurons281-283. For
example, centrally delivered NPY increases dopamine release at VTA dopamine efferent
sites281-283 and increases dopamine associated behaviors159,174,297-299 suggesting that NPY
increases the activity of dopamine neurons to stimulate dopamine release. In contrast,
Korotkova et al. have shown that NPY inhibits firing of VTA dopamine neurons in ex vivo slice
preparations217, indicating that NPY inhibits dopamine neurons, which is supported by our
studies showing that NPY activates an outward GIRK current and inhibits EPSCs in dopamine
neurons. We attempted to examine the net effect of NPY on dopamine neuron activity by
testing the effect of NPY on the firing rate of VTA dopamine neurons in the cell-attached
configuration in the presence and absence of inhibitors of synaptic transmission (DNQX and
picrotoxin). Due to the small effects of NPY on dopamine neuron firing rate in these
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experiments, we could not conclusively determine whether NPY had an excitatory, inhibitory,
or no effect on the activity of all the dopamine neurons tested, however. Thus, it is still unclear
whether the net effect of NPY on dopamine neuron activity in vivo would be excitatory or
inhibitory.
One possible explanation for NPY causing both excitatory and inhibitory effects on
dopamine neuron activity is that NPY could differentially modulate separate subpopulations of
VTA dopamine neurons through distinct mechanisms. NPY only affected a subset of VTA
dopamine neurons for each of the responses measured (direct current, EPSCs, IPSCs). Thus,
NPY could excite one subpopulation of dopamine neurons and inhibit another distinct
subpopulation of dopamine neurons. Historically, dopamine neurons have been thought of as a
uniform population of neurons, but recent research has demonstrated that there are
subpopulations of VTA dopamine neurons that project to different efferent target regions and
show distinct electrophysiological and molecular properties16,17,36,300. In addition, aversive
stimuli and rewards have also been shown to excite distinct subpopulations of dopamine
neurons16,17,36,300. Thus, NPY could excite a specific subpopulation of dopamine neurons while
inhibiting a distinct subset of neurons to differentially regulate distinct aspects of behavior (e.g.
reward vs. aversion). For example, dopamine neurons encoding reward and reinforcement
project to the nucleus accumbens while dopamine neurons encoding aversion project to the prefrontal cortex301. Thus, it is possible that NPY could excite dopamine neurons projecting to the
nucleus accumbens to promote food reward while inhibiting dopamine neurons projecting to the
pre-frontal cortex to decrease aversion. This possibility is supported by the overall effects of
NPY on food-motivated behavior, as injection of NPY either icv or into the VTA increases
operant responding for sucrose and food pellets in rats159,174,297, and this response is associated
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with increased dopamine release in the nucleus accumbens132,302. Further experiments will be
required to identify the net effect of NPY on overall dopamine neuron activity and dopamine
output, and to determine whether NPY is activating and inhibiting distinct subpopulations of
VTA dopamine neurons to promote food-seeking behaviors.
In summary, we have demonstrated that NPY modulates subsets of VTA dopamine
neurons through three independent mechanisms, including both pre-synaptic and post-synaptic
mechanisms. NPY directly inhibited VTA dopamine neurons through activation of a postsynaptic GIRK channel current, and indirectly inhibited VTA dopamine neurons through a presynaptic reduction in glutamate release. NPY also decreased GABAergic transmission onto
dopamine neurons through a pre-synaptic reduction in GABA release. These results advance
our understanding of how VTA dopamine neuron activity is regulated and provide further
understanding of how NPY interacts with the mesocorticolimbic dopamine system to regulate
feeding behavior.
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4.6

Figures

Figure 4.1: NPY concentration-dependently activated an outward current and reduced
membrane resistance (RM) in a subset of VTA dopamine neurons.
A-C. Sample traces (A), mean effect (B), and mean peak amplitude (C) of the NPY activated
current at different concentrations. D-E. Mean effect of NPY on RM (D) and mean RM before
and after NPY application (D) at different concentrations. Bars in A-B & D indicate time of
NPY application. n=6-7 cells from 5-6 mice for each group. Scale Bars: 25 pA/3 min. *p<0.05
**p<0.01

66

Figure 4.2: The NPY-induced current was mediated by NPY Y1Rs in VTA dopamine neurons.
A-C. The Y1R antagonist, BIBP3226 (1 µM), reversed the NPY (300 nM) induced current.
Sample trace (A) and mean response (B; n=4) of the NPY current before and during BIBP3326
application, and mean NPY current amplitude before and after BIBP3226 application (C; n=4).
D-E. Sample trace (D) and mean response (E; n=8) of VTA dopamine neurons pretreated with
BIBP3226 (1 µM) to NPY (100 nM). Bars in A-B & D-E indicate time of NPY and BIBP3226
application. Scale bars: 30 pA/2.5 min. *p<0.05
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Figure 4.3: The NPY-induced current in VTA dopamine neurons exhibited characteristics of a
G protein-coupled inwardly rectifying K+ (GIRK) channel.
A. Sample current traces resulting from slow voltage ramps (-100 mV to 0 mV 100 mV s-1)
before (black trace) and after NPY (100 nM; light grey trace) application, and 2 min after the
addition of Ba2+ (1 mM; NPY + Ba2+, dark grey trace) using a high K+ (10 mM) external
solution containing TTX (1 M). B. Sample trace of the net NPY (100 nM) induced current. C.
Mean current-voltage relationship of the NPY (100 nM) induced current. D-E. Mean effect (D)
and sample trace (E) of the NPY (100 nM) –induced current at a holding potential of -40 mV
before and during Ba2+ (1 mM) application using a high K+ (10 mM) external solution
containing TTX (1 M). Bars in D-E indicate time of NPY and Ba2+ application. n=5-7 cells
from 5-7 mice for each group. Scale bars: 25 pA/3 min.
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Figure 4.4: NPY and baclofen currents are affected by intracellular Ca2+ levels in VTA
dopamine neurons.
A-B. Sample traces (A) and mean peak amplitudes (B) of the NPY (100 nM) and baclofen (1
μM) induced currents using internal solutions containing 10 mM BAPTA (black trace) or 0.1
mM EGTA (grey trace). Bars in A indicate time of NPY and baclofen application. Scale bars:
50 pA/5 min. n=6-8 cells from 5-8 mice for each group. *p≤0.05 **p≤0.01
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Figure 4.5: NPY decreased EPSCs in a subset of VTA dopamine neurons through a presynaptic decrease in glutamate release.
A. Mean effect of NPY (100 nM) on EPSCs (n=10 cells from 10 mice) and sample trace
of an EPSC before (a; black trace) and after (b; grey trace) NPY. B-C. Mean EPSC amplitude
before and after NPY (100 nM) application for the EPSCs inhibited by NPY (B; n=7 of 10) and
for the EPSCs not affected by NPY (C; n=3 of 10). D-E. Mean effect of NPY (100 nM) on the
EPSC amplitude, PPR, and CV for the EPSCs inhibited by NPY (D; n=7 of 10) and for the
EPSCs not affected by NPY (E; n=3 of 10). F-G. Time course of the effect of NPY (100 nM)
on EPSC PPRs for the EPSCs inhibited by NPY (F; n=7 of 10) and for the EPSCs not affected
by NPY (G; n=3 of 10). H-I, J-K. Mean PPR (H-I) and mean CV (J-K) before and after NPY
(100 nM) application for the EPSCs inhibited by NPY (H,J; n=7 of 10) and for the EPSCs not
affected by NPY (I,K; n=3 of 7). L-M. Mean EPSC response to NPY (100 nM) (L) and mean
EPSC amplitude after NPY (100 nM) application (M) in neurons in which NPY caused an
outward current (n=3 of 10) compared to neurons that did not show an NPY-induced current
(n=4 of 10). Bars in A, F-G, & L indicate time of NPY application. Scale Bar: 200 pA/10 ms.
*p≤0.05 **p≤0.01
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Figure 4.6: NPY inhibited IPSCs in a subset of VTA dopamine neurons through a pre-synaptic
decrease in GABA release.
A. Mean effect of NPY (100 nM) on IPSCs (n=6 cells from 5 mice) and sample trace of an
IPSC before (a; black trace) and after (b; grey trace) NPY. B. Mean IPSC amplitude before and
after NPY (100 nM) application for the IPSCs inhibited by NPY (n=4 of 6). C. Mean effect of
NPY (100 nM) on the IPSC amplitude, PPR, and CV for the IPSCs inhibited by NPY (n=4 of
6). D. Time course of the effect of NPY (100 nM) on IPSC PPRs for the IPSCs inhibited by
NPY (n=4 of 6). E-F. Mean PPR (E) and mean CV (F) before and after NPY (100 nM)
application for the IPSCs inhibited by NPY (n=4 of 6). Bars in A & D indicate time of NPY
application. Scale Bar: 200 pA/20 ms. *p≤0.05 **p≤0.01
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5

α-MSH INCREASES ACTIVITY OF MC3R-EXPRESSING NEURONS IN THE
VENTRAL TEGMENTAL AREA

5.1

Abstract
The mesocorticolimbic dopamine system, the brain’s reward system, regulates multiple

behaviors including food intake and food reward. There is substantial evidence that the
melanocortin system of the hypothalamus, an important neural circuit controlling homeostatic
feeding and body weight, interacts with the mesocorticolimbic dopamine system to affect
feeding, food reward, and body weight. For example, melanocortin-3 receptors (MC3Rs) are
expressed in the ventral tegmental area (VTA), and our lab previously showed that intra-VTA
injection of the MC3R agonist, MTII, decreases home-cage food intake and operant responding
for sucrose pellets. The cellular mechanisms underlying the effects of intra-VTA -MSH on
feeding and food reward are unknown, however. To determine how -MSH acts in the VTA to
affect feeding, we performed electrophysiological recordings in acute brain slices from mice
expressing EYFP in MC3R neurons to test how -MSH affects the activity of VTA MC3R
neurons. -MSH significantly increased the firing rate of VTA MC3R neurons, but it did not
increase the activity of non-MC3R expressing VTA neurons. In addition, the -MSH-induced
increase in MC3R neuron activity was independent of fast synaptic transmission and
intracellular Ca2+ levels. Furthermore, we show that the effect of -MSH on MC3R neuron
firing rate is likely activity dependent and does not occur through a decrease in threshold
potential. Overall, these studies provide an important advancement in the understanding of how
-MSH acts in the VTA to affect feeding and food reward.
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5.2

Introduction
The world health organization estimates that obesity rates have nearly tripled worldwide

since 19751. The rapid rise in obesity rates is a major health concern as obesity increases the
risk for many diseases such as heart disease, diabetes, cancers, and stroke2. The increase in
obesity rates is largely attributed to an increase in food consumption4-7. Thus, understanding the
mechanisms of food intake and weight gain is important for the development of new effective
treatments to prevent and reverse obesity.
The melanocortin system has been widely shown to play an important role in the control
of feeding and body weight. This system encompasses two neuronal populations in the arcuate
nucleus of the hypothalamus, pro-opiomelanocortin (POMC) expressing neurons and agoutirelated protein/neuropeptide-Y (AgRP/NPY) expressing neurons, the peptides expressed by
these neurons, and the downstream receptors of these peptides165. POMC is a propeptide that is
post-translationally processed to produce the melanocyte stimulating hormones (α-, β-, and γMSH). α-, β-, and γ-MSH are agonists to the centrally expressed melanocortin receptors,
melanocortin-3 and melanocortin-4 receptors (MC3/4Rs), while AgRP is an inverse-agonist to
the MC3/4Rs165. AgRP/NPY and POMC neurons respond to an animal’s energy state and
function in an opposing manner. For example, an energy deficit or hunger state activates
AgRP/NPY neurons303,304 while an energy surplus or satiated state activates POMC
neurons305,306. In addition, activation of AgRP/NPY neurons or injection of MC3/4R
antagonists increases feeding211,219,307,308, while activation of POMC neurons or injection of
MC3/4R agonists decrease feeding211,219,220,309. The melanocortin system is clearly an important
regulator of food intake, and substantial evidence indicates that this system interacts with other
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brain nuclei and neural systems, including the mesocorticolimbic dopamine system, to regulate
food intake and body weight.
The mesocorticolimbic dopamine system is the primary circuit for reward and motivated
behavior and also regulates food reward, feeding, and body weight15,165,270,271. The
mesocorticolimbic dopamine system is comprised of dopamine neurons in the VTA and the
downstream targets of dopamine neurons such as the NAc, prefrontal cortex, olfactory tubercle,
and hippocampus. Numerous studies show the importance of dopamine for food intake and
food reward. For example, ablation of dopamine neurons causes mice to become aphagic133,
and blocking dopamine receptors systemically or in the NAc decreases operant responding for
food in rats132,273,274. There is also substantial evidence that intra-VTA injection of a number of
feeding-related peptides alters food intake and food reward168. This includes injection of
analogs of α-MSH and AgRP into the VTA. For example, our lab has shown that injection of
the MC3R agonist, MTII, directly into the VTA decreases home-cage food intake, the intake of
sucrose and saccharin intake in 2-bottle choice tests, and operant responding for sucrose pellets,
whereas injection of the MC3R antagonist, SHU9119, into the VTA increases home-cage food
intake and operant responding for sucrose pellets172,173,175. Nevertheless, how α-MSH acts in
the VTA at the cellular level to regulate feeding and other reward related behaviors is unknown.
Intra-VTA α-MSH may affect food intake and food reward by regulating VTA
dopamine neuron activity. For example, it has been known since the 1980s that intra-VTA
injection of α-MSH increases dopamine turnover in the NAc229,230, and intra-VTA α-MSH and
MC3/4R agonists increase dopamine dependent behaviors, such as rearing, grooming, and
locomotor activity227-230. Furthermore, additional evidence indicates that the melanocortin and
mesocorticolimbic dopamine systems interact. POMC and AgRP neurons project to the
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VTA222,278, and MC3/4Rs are expressed in dopamine and non-dopamine VTA neurons223,225,226.
The MC3R is expressed at much higher levels in the VTA than the MC4R, however223,225,226,
suggesting that the effects of α-MSH and AgRP in the VTA are likely due to actions on
MC3Rs. Thus, -MSH can clearly act in the VTA to affect food intake, food reward, and other
reward behaviors, likely through activation of dopamine neurons expressing the MC3R.
However, how α-MSH acts on MC3R-expressing VTA dopamine neurons to regulate food
intake and reward behavior and to increase dopamine turnover in the NAc is unknown. Thus, in
these studies, we tested whether α-MSH increases the activity of VTA dopamine neurons
expressing MC3Rs by using electrophysiology in brain slices from transgenic mice expressing
EYFP in MC3R neurons.

5.3

Materials and Methods
Animals: Male and female transgenic mice expressing EYFP in MC3R neurons (5-14

weeks old) on a mixed C57/129 background were used in all experiments. Mice were generated
by crossing transgenic mice expressing Cre recombinase under the MC3R promoter (generously
provided by Dr. David P. Olson, University of Michigan) with a Cre inducible EYFP transgenic
mouse line (Ai3 mice from The Jackson laboratory). All protocols and procedures were
approved by the Institutional Animal Care and Use Committee at Georgia State University, and
conformed to the NIH Guide for the Care and Use of Laboratory Animals.
Slice preparation and Electrophysiology: Acute brain slices were prepared similar to
what has been previously described234-236. Briefly, adult mice were anesthetized with
isofluorane and decapitated. The brain was then removed and placed in carbogen (95% O2 and
5% CO2) saturated ice-cold sucrose cutting solution containing (in mM) 205 sucrose, 2.5 KCl,
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0.5 CaCl2, 1.25 NaH2PO4, 7.5 MgCl2, 11.1 glucose, 21.4 NaHCO3, and 0.6 kynurenic acid. A
brain block containing the VTA was made, and pseudo-horizontal sections (220 m) were cut
with a vibrating blade microtome. Slices were then incubated in artificial cerebral spinal fluid
(aCSF) containing (in mM) 126 NaCl, 2.5 KCl, 2.4 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 11.1
glucose, 21.4 NaHCO3, and 1 kynurenic acid (~ 35C) for ~ 30 min before recording. Slices
were placed in a recording chamber and perfused with carbogen-saturated aCSF at a flow rate of
approximately 1-2 ml/min. Whole-cell and loose cell-attached recordings were made using an
Axon multiclamp 700B microelectrode amplifier and Axograph software. MC3R-expressing
neurons were identified by the presence of EYFP using a fluorescence microscope.
Cell firing was recorded in either the loose-cell attached or whole-cell configuration.
Loose cell-attached recordings were obtained with electrodes (7.0-10.0 M) filled with a
NaHEPES based internal solution containing (in mM) 135 NaHEPES and 20 NaCl, adjusted to
290 mOsm with water. Whole-cell recordings were obtained with electrodes (2.0-3.0 M)
filled with a potassium gluconate (KGluconate) based internal solution containing (in mM) 128
KGluconate, 10 NaCl, 1 MgCl2, 10 HEPES, 2 ATP, 0.3 GTP, 10 creatine phosphate, and 10
BAPTA or 1 EGTA. The internal solution contained EGTA for the experiments examining the
effect of α-MSH on MC3R neuron activity under reduced calcium buffering conditions. The
internal solution contained BAPTA for all other whole-cell recordings. Corrections were not
made for the liquid junction potential, which was calculated to be the following for each internal
solution used: KGluconate 10 mM BAPTA, 13.9; KGluconate 1 mM EGTA, 14.7. Series
resistance values were approximately 3-15 M. If the series resistance increased by more than
20%, the experiment was terminated or excluded from analysis. Cell firing was recorded in
voltage-clamp mode for loose-cell attached recordings and current-clamp mode for whole-cell
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recordings. Whole-cell recordings were conducted in the presence of fast synaptic blockers (10
μM DNQX and 100 μM picrotoxin), and if the cell was not firing positive current was injected
(5- 55 pA). In addition, if the cell stopped firing or did not fire for at least 1 min during
baseline recordings or during the first 2 min of adding α-MSH, the experiment was terminated
or excluded from analysis. Membrane potential was recorded in current-clamp mode in the
presence of fast synaptic blockers and tetrodotoxin (1 μM TTX). For experiments testing the
effect of α-MSH on current-step evoked action potentials, the neurons were held at ~ -70 mV
and 2-sec current steps of 5 pA were applied at increasing amplitudes (5-50 pA) with a 1-sec
inter-step interval. The current-step protocol was repeated every minute, and if the current steps
failed to evoke action potentials or if the number of evoked action potentials decreased over
time during baseline recording, the experiment was terminated. For all experiments, the change
in firing rate or membrane potential was calculated as the difference between the average firing
rate or membrane potential at 5 min before α-MSH treatment and the average firing rate or
membrane potential at 4-6 min after α-MSH treatment. For all experiments, cells were held for
at least 10 min prior to drug application to allow for diffusion of the internal solution into the
cell and to ensure stability of the recording prior to drug addition.
Drugs: α-MSH was purchased from Bachem (Torrance, CA). TTX was purchased from
Tocris Biosciences (Minneapolis, MN). All other reagents were from common commercial
sources.
Data Analysis and Statistics: Data are represented as the mean +/- SEM unless otherwise
noted. Data were stored and analyzed using Axograph X (v1.3.5), LabChart (v7.3.6;
ADInstruments), and Excel (v14.0; Microsoft Corporation) software. Statistics were calculated
using SigmaStat (v11.0; Systat Software, Inc.). Data were initially tested for normality using
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the Shapiro-Wilk test and were then analyzed with Student’s t-tests, Wilcoxon signed-rank tests,
or ANOVAS with Tukey’s post-hoc tests as appropriate with a significance level of p<0.05 set
a priori.

5.4

Results
To determine whether α-MSH affects the activity of MC3R expressing VTA neurons

(‘VTA MC3R neurons’), we first tested whether α-MSH changed the spontaneous firing rate of
VTA MC3R neurons in the loose-cell attached configuration. α-MSH (1 μM) significantly
increased the spontaneous firing rate of VTA MC3R neurons by 0.41 +/- 0.07 Hz (Fig. 5.1;
before α-MSH, 2.92 +/- 0.41 Hz; after α-MSH, 3.33 +/- 0.39 Hz). Out of the 8 MC3R neurons
tested, all exhibited an action potential width ≥1.2 ms suggesting that the MC3R neurons tested
were dopaminergic. A broad action potential width is a physiological characteristic of
dopamine neurons that has repeatedly and reliably been used to identify dopamine neurons68,238240

. Thus, α-MSH increases the firing of VTA dopamine neurons expressing MC3Rs.
We next confirmed and extended these findings by testing whether α-MSH increases the

firing rate of VTA MC3R neurons in the whole-cell current-clamp configuration. In addition,
we included blockers of fast synaptic currents (10 μM DNQX, 100 μM picrotoxin) in the bath
solution to confirm that the α-MSH induced increase in MC3R neuron firing rate was due to
direct action on MC3Rs and not changes in synaptic transmission. α-MSH (1 μM) significantly
increased the firing rate of MC3R neurons by 0.42 +/- 0.11 Hz in the presence of fast synaptic
blockers (Fig. 5.2A-C; before α-MSH, 1.17 +/- 0.21 Hz; after α-MSH, 1.59 +/- 0.15 Hz).
Intracellular Ca2+ plays a key role in VTA dopamine neuron excitability, firing rate, and burst
firing56,57,69, so we next tested whether reduced Ca2+ buffering affected the α-MSH induced
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increase in MC3R neuron firing rate using an internal solution containing a low Ca2+ buffer (1
mM EGTA). α-MSH (1 μM) also significantly increased the firing rate of MC3R neurons using
the 1 mM EGTA internal solution by 0.51 +/- 0.17 Hz (Fig. 5.2D-E; before α-MSH, 1.28 +/0.34 Hz; after α-MSH, 1.78 +/- 0.47 Hz), with no significant difference between the magnitudes
of α-MSH induced increase in firing rate between the two groups (10 mM BAPTA, 0.42 +/0.11 Hz vs. 1 mM EGTA, 0.51 +/- 0.17 Hz; p=0.673). Thus, α-MSH increases the firing rate of
VTA MC3R neurons through a mechanism independent of fast synaptic transmission and
intracellular Ca2+ levels.
MC3Rs are only expressed in a subset of VTA neurons225, so we next tested whether the
α-MSH induced increase in VTA MC3R neuron firing rate was specific to VTA MC3R
neurons. α-MSH did not increase the firing rate of non-MC3R expressing VTA neurons (Fig.
5.3; before α-MSH, 0.70 +/- 0.14 Hz, after α-MSH: 0.49 +/- 0.13 Hz; p=0.104). There was a
trend toward a decrease in firing rate by -0.2 +/- 0.11, but this decrease was not statistically
significant (Fig. 5.3C). Therefore, α-MSH induced increase in VTA neuron firing appears to be
specific to MC3R-expressing VTA neurons.
α-MSH could increase the activity of VTA MC3R neurons by direct depolarization or by
modifying the firing properties of the cell (e.g. threshold) independent of a direct change in
membrane potential. To determine if α-MSH directly depolarizes MC3R neurons, we tested the
effect of α-MSH on membrane potential in the presence of TTX (1 μM), DNQX (10 μM), and
picrotoxin (100 μM). α-MSH (1 μM) slightly increased the membrane potential of MC3R
neurons, but this increase was not statistically significant (Fig. 5.4; before α-MSH, -53.7 +/- 3.7
mV; after α-MSH -52.4 +/- 3.6 mV; p=0.177; Mean depolarization = 1.34 +/- 0.84 mV).
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We then tested whether α-MSH altered VTA MC3R neuron firing independent of a
direct depolarization by testing the effect of α-MSH on current-step evoked action potentials.
The neurons were held at ~ -70 mV and a set of current steps of increasing amplitude (5-50 pA
in 5 pA increments; 2-sec each; 1-sec inter-step interval) were applied every minute. α-MSH (1
μM) did not significantly affect rheobase (the minimal current required to reach threshold
potential and generate an action potential) (Fig. 5.5B,E; before α-MSH, 26.9 +/- 3.5 pA; after αMSH, 25 +/- 3 pA; p=0.35) or membrane potential (Fig. 5.5C-D; before α-MSH, -70.6 +/- 0.87
mV; after α-MSH, 68.1 +/- 1.7 mV; p=0.181). However, α-MSH (1 μM) did significantly
increase the number of current-evoked action potentials at the 35, 40, 45, and 50 pA current
steps in MC3R neurons (Fig. 5.5A-B; significant main effect of current step (F(9, 63)=22.135,
p<0.001) and significant current-step× α-MSH interaction (F(9,63)=3.227, p=0.003)). The
current-step evoked action potentials were further analyzed at the 40 pA current step, because
this step consistently evoked 3-4 action potentials at baseline in 7 out of 8 neurons tested. One
cell was excluded from this analysis, because the 40 pA current step failed to consistently evoke
action potentials. α-MSH significantly increased the inter-spike interval at the 40 pA current
step (Fig. 5.5F; before α-MSH, 119.7 +/- 20.8 ms; after α-MSH, 90.9 +/- 12.1 ms), and there
was a trend towards a decrease in the latency to the first spike at the 40 pA current step (Fig.
5.5G; before α-MSH, 1.07 +/- 0.13 sec; after α-MSH, 0.85 +/- 0.07 sec; p=0.131). Thus, αMSH facilitates MC3R neuron firing through an activity dependent mechanism that does not
appear to involve direct depolarization or a change in rheobase or threshold potential.
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5.5

Discussion
We have shown that α-MSH significantly increases the firing rate of VTA MC3R

neurons through an activity dependent mechanism, as α-MSH increased the activity of MC3R
neurons only when the neurons were firing. α-MSH did slightly increase the membrane
potential of MC3R neurons, and it is possible that this slight increase in membrane potential
causes a significant increase in MC3R neuron firing, however. In addition, α-MSH did not
affect rheobase in MC3R neurons, suggesting that α-MSH does not increase the firing rate of
MC3R neurons by lowering threshold potential. Furthermore, α-MSH increased the firing rate
through a mechanism independent of fast synaptic transmission and intracellular Ca2+ levels.
Thus, our results suggest α-MSH increases the firing rate of VTA MC3R neurons through an
activity dependent mechanism that is independent of intracellular Ca2+ levels or altered synaptic
transmission onto VTA MC3R neurons.
The effect of α-MSH on VTA MC3R neurons likely occurs through activation of
MC3Rs, as MC3Rs are highly expressed in the VTA223,225. It is possible that α-MSH could
mediate its effect on MC3R neurons by acting on MC4Rs as well, but this seems unlikely.
Although MC4Rs are also expressed in the VTA, they are expressed at much lower levels
compared to MC3Rs223,225,226, and MC4Rs are most abundantly expressed in caudal regions of
the VTA, while MC3Rs are expressed throughout the rostral-caudal extent of the VTA225.
Thus, although we cannot rule out the possibility that the effects of α-MSH on VTA MC3R
neuron activity are also mediated by MC4Rs in some of the MC3R neurons tested, this does not
seem likely.
MC3Rs are expressed in both VTA dopamine and non-dopamine neurons (dopamine: ~
57%; non-dopamine: ~43%)225. The identity of MC3R non-dopamine neurons is currently
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unknown, and these neurons may be GABAergic or glutamatergic neurons, as both are found in
the VTA28,30,31. Previous studies have shown that intra-VTA α-MSH increases dopamine
release in the NAc and dopamine-dependent behaviors suggesting that α-MSH increases VTA
dopamine neuron activity227-230,232,233. In addition, γ-MSH increases the firing rate of a subset of
VTA dopamine neurons in rats310. In agreement, our results suggest that α-MSH increases the
firing rate of VTA dopamine neurons expressing MC3Rs. All of the MC3R neurons tested in
the cell-attached recordings had broad action potential widths (≥ 1.2 ms), which has been shown
to reliably identify mouse VTA dopamine neurons in cell-attached recordings238,239. Thus, αMSH likely increases VTA dopamine-MC3R neuron firing rate. However, it is possible that the
MC3R neurons tested in the whole-cell recordings could have been both dopamine and nondopamine neurons, as the effectiveness of previous criteria used to identify dopamine neurons in
whole-cell recordings has more recently been brought into question. For example, action
potential width does not reliably identify VTA dopamine neurons in whole-cell recordings in
mice239, so it could not be used to definitively identify the MC3R neurons in the whole-cell
recordings here. Similarly, another electrophysiological marker for dopamine neurons,
hyperpolarization-activated cation current (H-current), could not be used to identify MC3R
neurons. Only a few MC3R neurons tested exhibited H-current, and electrophysiological
markers of VTA dopamine neurons, such as H-current, are heterogeneous and depend on
dopamine neuron projection target16,35,311,312. Thus, it is difficult to conclusively determine
whether the VTA MC3R neurons studied here were all dopaminergic, or also contained GABA
or glutamate neurons. In conclusion, we have shown that α-MSH likely increases the firing rate
of VTA dopamine MC3R-expressing neurons, but α-MSH may increase the firing rate of VTA
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GABA and/or glutamate MC3R-expressing neurons as well, and further studies will be required
to conclusively identify the specific subtypes of VTA MC3R neurons responding to α MSH.
We also showed that α-MSH does not significantly increase the firing rate of non-MC3R
expressing VTA neurons, but there was a trend towards a decrease in firing rate in these studies,
as α-MSH reduced the firing rate of 4 out of 5 of the non-MC3R neurons tested. This decrease
in firing rate may be due to run down, because the firing rate slowly ran down in most of the
recorded neurons. Alternatively, α-MSH may decrease the firing rate of non-MC3R expressing
VTA dopamine neurons through activation of dopamine D2 receptors (D2R). VTA dopamine
neurons release dopamine from their soma and dendrites95-99, and this somatodendritic release
inhibits neighboring dopamine neurons through D2R mediated activation of G-coupled inward
rectifying potassium (GIRK) channels98,100-102. Our results suggest α-MSH likely increases the
activity of VTA dopamine-MC3R neurons. Increased activity of dopamine-MC3R neurons
could cause an increase in somatodendritic dopamine release and inhibition of neighboring
VTA dopamine neurons, but this possibility remains to be tested.
MC3Rs are G protein-coupled receptors that signal through Gs and thus activate
adenylyl cyclase and subsequently cAMP and PKA223. However, additional experiments have
demonstrated that the MC3R is coupled to other G-proteins and can activate other signaling
pathways. For example, activating MC3Rs in HEK293 cells activates MAP kinase through a Gi
protein-PI3K signaling pathway313. It is possible that α-MSH increases MC3R neuron activity
by activating one of these kinases and subsequently increasing or decreasing the conductance of
an ion channel through phosphorylation of that ion channel, but the signaling cascade activated
by α-MSH acting on MC3Rs in VTA neurons is currently unknown. Thus, further experiments
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are needed to determine how -MSH increases VTA MC3R neuron firing rate, and the
intracellular signaling pathway activated by MC3Rs in VTA neurons.
Previous studies have shown that activation of MC3Rs increases intracellular Ca2+ in
neurons314-316 and one study showed -MSH increases intracellular Ca2+ in MC3R-expressing
HEK293 cells317. Intracellular Ca2+ is an important regulator of dopamine neuron
excitability56,57,69 and increasing intracellular Ca2+ increases dopamine neuron burst firing57.
Thus, -MSH could alter VTA MC3R neuron activity through the alteration of intracellular
calcium levels, but our results suggest that the effect of -MSH on MC3R neuron firing rate is
independent of intracellular Ca2+ levels. -MSH increased the firing rate of MC3R neurons
under both increased (10 mM BAPTA) and reduced (1 mM EGTA) intracellular Ca2+ buffering
conditions, and there was no significant difference in the magnitude of the effect of -MSH
with the two conditions. Thus, -MSH induced increase in VTA MC3R neuron firing is not
Ca2+ dependent.
In summary, we have shown that -MSH increases the firing rate of MC3R expressing
VTA neurons through an activity dependent mechanism. These results advance our
understanding of how intra-VTA -MSH regulates food intake, food reward, and other
dopamine dependent behaviors, and how intra-VTA -MSH increases dopamine turnover in the
NAc.
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5.6

Figures

Figure 5.1: -MSH increased the spontaneous firing rate of VTA MC3R neurons in loose cellattached recordings.
A. Sample traces of a MC3R neuron before (black trace) and after (grey trace) -MSH (1 μM).
B. Mean effect of -MSH on the firing rate of MC3R neurons. C. Mean firing rate of MC3R
neurons before and after -MSH. n= 8 neurons from 7 mice. Scale Bars: 1 sec. *p<0.001
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Figure 5.2: -MSH increased the firing rate of VTA MC3R neurons in whole-cell current clamp
recordings in the presence of inhibitors of fast synaptic transmission (DNQX: 10 μM;
picrotoxin: 100 μM).
A. Sample traces of the firing rate of a MC3R neuron before (black trace), during, and after
(grey trace) -MSH (1 μM) application. B,D. Mean effect of -MSH on the firing rate of
MC3R neurons using an internal solution containing 10 mM BAPTA (B) or 1 mM EGTA (D).
C,E. Mean firing rate of MC3R neurons before and after -MSH using an internal solution
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containing 10 mM BAPTA (C) or 1mM EGTA (E). n= 6 neurons from 6 mice for each group.
Scale Bars: top trace, 40 mV/1 min; bottom trace, 40 mV/4 sec. *p<0.05

Figure 5.3: -MSH did not increase the firing rate of non-MC3R expressing VTA neurons in
whole-cell current clamp recordings in the presence of inhibitors of fast synaptic transmission
(DNQX: 10 μM; picrotoxin: 100 μM).
A. Sample traces of the firing rate of a non-MC3R neuron before (black trace), during, and after
(grey trace) -MSH (1 μM) application. B. Mean effect of -MSH on the firing rate of nonMC3R neurons. C. Mean firing rate of non-MC3R neurons before and after -MSH. n= 5
neurons from 5 mice. Scale Bars: top trace, 50 mV/1 min; bottom trace, 40 mV/4 sec.
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Figure 5.4: -MSH did not significantly affect the membrane potential of VTA MC3R neurons
in the presence of TTX (1 μM).
A. Mean effect of -MSH (1 μM) on the membrane potential of MC3R neurons. B. Mean
membrane potential of MC3R neurons before and after -MSH. n= 6 neurons from 6 mice.
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Figure 5.5: -MSH increased the number of current-step evoked action potentials but did not
affect rheobase in VTA MC3R neurons.
Current steps (2 sec) of increasing amplitude (5-50 pA) were applied every minute before,
during, and after -MSH (1 μM) application. A. Sample traces of a MC3R neuron before
(black trace) and after (grey trace) -MSH. B. Mean effect of -MSH on the number of action
potentials evoked by incrementing 5 pA current-steps (5-50 pA). C-D. Mean effect of -MSH
on membrane potential (C) and mean membrane potential before and after -MSH (D) for the
MC3R neurons in B. E-F. Mean rheobase (the minimum current step required to initiate an
action potential; E), mean inter-spike interval at the 40 pA step (F), and mean latency to the first
spike at the 40 pA step (G) before and after -MSH. n= 7-8 neurons from 6-7 mice for each
group. Scale Bars: left traces, 40 mV/5 sec; right traces, 40 mV/2 sec. *p<0.05
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6

CONCLUSIONS

In summary, I have shown here that overall neurotensin appears to increase VTA
dopamine neuron activity by directly activating a slow non-selective cationic current and by
decreasing D2R and GABAB IPSCs234. In contrast, NPY appears to decrease the activity of a
subset of VTA dopamine neurons by directly activating an inhibitory GIRK current and by
decreasing glutamatergic transmission onto VTA dopamine neurons, although NPY likely
increases the activity of a subset of VTA dopamine neurons through dis-inhibition as NPY also
decreases GABAergic transmission onto a subset of VTA dopamine neurons236. Lastly, I have
shown that -MSH increases the activity of VTA MC3R-expressing neurons. Neurotensin and
-MSH are both anorexigenic peptides that decrease feeding and food reward when injected
into the VTA169-173,175 whereas NPY is an orexigenic peptide that increases operant responding
for food when injected into the VTA174. If only the results presented here are considered, then
the data suggest that anorexigenic peptides increase dopamine neuron activity to decrease
feeding and food reward while orexigenic peptides decrease dopamine neuron activity to
increase food reward, but a review of the literature reveals the opposite to be true168. For
example, insulin and leptin (anorexigenic) decrease dopamine neuron activity318-320 while
ghrelin (orexigenic) increases dopamine neuron activity321. Orexigenic peptides usually
increase dopamine neuron activity and dopamine release while anorexigenic peptides have been
shown to both increase and decrease dopamine neuron activity and dopamine release168.
Nonetheless, the theory that increased dopamine neuron activity and dopamine release lead to
increased food intake is too simple to adequately describe how the mesocorticolimbic dopamine
system regulates food intake. In light of this, it is unclear how anorexigenic and orexigenic
peptides interact with the mesocorticolimbic dopamine system to regulate food intake, food
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reward, and weight gain. Three possible models are described below as to how neuropeptides
act in the VTA to regulate food intake and food reward: 1- neuropeptides regulate tonic and
burst firing through different mechanisms (Fig. 6.1), 2- neuropeptides affect specific
subpopulation of dopamine neurons to control distinct behaviors (Fig. 6.2), 3- neuropeptides
regulate VTA glutamate and GABA neuron activity (Fig. 6.3). In addition, how the effects of
neurotensin, NPY, and -MSH on VTA dopamine neuron activity contribute to these models is
described below. Finally, I describe how VTA dopamine neurons may integrate peptide signals
of energy state to regulate feeding along with the future direction of the projects presented here.

6.1

Model 1- Neuropeptides regulate tonic and burst firing through different
mechanisms
Neuropeptides may not increase or decrease overall dopamine neuron activity to

modulate food intake and food reward. Rather, it is possible that neuropeptides affect food
intake and food reward by changing only tonic or only burst dopamine neuron firing or by
decreasing tonic firing but increasing burst firing and vice versa (Fig. 6.1). For example, testing
the effect of evoking tonic or burst firing in VTA dopamine neurons on behavior has revealed
that evoking tonic vs. burst firing affects reward consumption and reward-behavior differently.
Previous studies suggest that tonic firing affects reward consumption whereas burst firing
affects reward behavior. Indeed, evoking tonic firing in VTA dopamine neurons using
optogenetics decreases sucrose and ethanol consumption in a two bottle-choice test322,323 while
evoking burst firing has no effect on ethanol consumption322. In contrast, evoking burst firing
in VTA dopamine neurons using optogenetics causes conditioned place preference whereas
evoking tonic firing does not324. In addition, reducing burst firing by knocking out NMDARs in
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VTA dopamine neurons has no effect on food consumption, but does impair conditioned place
preference for food and cue-dependent learning tasks80; thus, burst firing is important for reward
behavior and cue-induced learning. Numerous studies also show that evoking burst firing in
VTA dopamine neurons enhances reward reinforcement learning. For example, optogenetically
evoking burst firing in dopamine neurons reinforces lever pressing325, enhances lever pressing
for food reward, and reactivates food-seeking behavior after extinction training in mice302.
Thus, feeding neuropeptides may affect tonic and burst firing differently to regulate food intake
and food reward.
The different effects of tonic and burst firing on food intake and reward behavior may
explain why both anorexigenic and orexigenic neuropeptides have seemingly excitatory effects
on VTA dopamine neuron activity but opposite effects on feeding behavior. Furthermore, these
different effects of tonic and burst firing on behavior may explain why some peptides have both
excitatory and inhibitory effects on VTA dopamine neuron activity. I have shown here that
NPY has both excitatory and inhibitory effects on dopamine neuron activity236, and it was
previously shown that intra-VTA NPY increases operant responding for sucrose pellets but has
no effect on free feeding174. Thus, taken from what is known about the effects of tonic and
burst firing on behavior, NPY may increase burst firing to enhance food reinforcement
behavior. Indeed, central NPY increases operant responding for food to equivalent levels as
food restriction159, and food restriction enhances dopamine neuron burst firing161 and dopamine
responses to sucrose, food intake, and operant responding for food151-154,326. Furthermore,
centrally injected ghrelin, an orexigenic peptide like NPY, enhances the phasic dopamine
response in the NAc to a reward-predicting cue and to pellet retrieval153,327. NPY may increase
dopamine neuron burst firing through its excitatory effect of reducing GABAergic transmission,
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as GABAA receptor antagonism also increases dopamine neuron burst firing86,87. Conversely,
the inhibitory effects of NPY on VTA dopamine neuron activity may decrease tonic firing of
dopamine neurons. Indeed, NPY levels increase during fasting328,329 and fasted animals do have
lower basal levels of dopamine in the striatum149,150,330, which is set by the tonic release of
dopamine. Thus, NPY may reduce tonic firing and basal dopamine levels through inhibitory
actions but enhance burst firing and phasic dopamine release through excitatory actions. These
opposing effects on tonic and burst firing would increase the change in dopamine from baseline
during phasic dopamine release and may explain how intra-VTA NPY increases reward
behavior. If the hypothesis described here holds true, then changes in the amount of dopamine
from baseline may regulate food intake and reward behavior rather than the absolute amount of
dopamine. Thus, higher basal levels of dopamine may occlude phasic dopamine signals and
reduce the change in dopamine from baseline during phasic release and decrease food intake
and reward behavior. In addition, increases in tonic dopamine release may further decrease
phasic dopamine release through an auto-inhibitory feedback mechanism323. For example,
D2Rs are located on dopamine neuron afferent terminals and tonic dopamine release may
inhibit phasic dopamine release through dopamine mediated D2R activation. In conclusion,
orexigenic peptides, such as NPY, may enhance burst firing and decrease tonic firing to increase
food intake and food reward (Fig. 6.1).
As described above, anorexigenic and orexigenic neuropeptides have seemingly
excitatory effects on VTA dopamine neuron activity. I have shown that the anorexigenic
peptide neurotensin increases the activity of dopamine neurons234 and that the anorexigenic
neuropeptide -MSH increases VTA MC3R neuron activity. Previous studies have shown that
-MSH and neurotensin both decrease food intake and reward behavior when injected into the
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VTA169-173,175. Therefore, in agreement with the above hypothesis, -MSH and neurotensin
may increase dopamine neuron tonic firing and increase basal dopamine release to decrease
food intake (Fig. 6.1). Neurotensin has also been shown to have inhibitory effects on dopamine
neurons as neurotensin increases evoked GABAA currents in SNc dopamine neurons331 and
decreases evoked EPSCs in VTA dopamine neurons332,333. These effects of neurotensin may
decrease bursting in dopamine neurons, because antagonizing glutamate receptors abolishes
burst firing331,332 and GABAA receptor agonist block NMDA induced burst firing92,93. Thus
overall, -MSH and neurotensin may increase dopamine neuron tonic firing while neurotensin
may also decrease dopamine neuron burst firing through its inhibitory effects to decrease food
intake and food reward (Fig. 6.1). Similarly, insulin (anorexigenic hormone) increases the
firing rate of a subpopulation of VTA dopamine neurons334, but also causes LTD of
glutamatergic transmission320. Thus intra-VTA insulin may increase dopamine neuron tonic
firing but decrease burst firing through a reduction in glutamate transmission to decrease
feeding. In addition, drugs of abuse such as cocaine and amphetamine also increase dopamine
levels in the NAc but decrease food intake. Nevertheless, drugs of abuse do increase other
dopamine dependent behaviors, such as locomotor behavior, and interestingly both neurotensin
and -MSH have also been shown to increase locomotor behavior188,189,228,229. Thus, increases
in basal dopamine levels seem to reduce food intake and food reward but may decrease feeding
behavior because of increased activity levels.
Another component of dopamine neuron activity is the pauses in burst firing. Pauses
occur in behaving animals when an unexpected reward is omitted or is less than what is
expected and after spontaneous bursts and in vitro stimulated bursts; thus, pauses are an
important component of the reward prediction error. Interestingly, high-frequency stimulation
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that mimics burst firing potentiates GABABR and D2R mediated GIRK currents127 while low
frequency stimulation that mimics tonic firing decreases GABABR and D2R mediated GIRK
currents126,127. Thus if GABABR and D2R mediated GIRK currents mediate pauses in burst
firing as has been hypothesized69,98, then it is fitting that they would be potentiated by burst
firing and attenuated by tonic firing. I have shown that neurotensin inhibits GIRK currents,
while NPY activates a GIRK current234,236. If NPY does promote burst firing to increase food
reward, then the NPY caused GIRK current may contribute to pauses in burst firing. Likewise,
if neurotensin disrupts burst firing and increases basal dopamine levels, then neurotensininduced inhibition of GIRK currents may disrupt the pauses in burst firing and increase tonic
dopamine neuron firing.
It has been argued here that neuropeptides may affect food intake and food reward by
modulating either tonic or burst dopamine neuron firing or by modulating tonic and burst firing
through different mechanisms, but this does not exclude the possibility that neuropeptides
regulate feeding by changing the overall activity of dopamine neurons. Orexigenic and
anorexigenic neuropeptides both increase dopamine neuron activity, and it may be that increases
in dopamine neuron activity and dopamine release both increase and decrease food intake. For
example, it could be that the amount of dopamine that causes a feeding response follows an
inverted-u curve such that high and low levels of dopamine decrease feeding, whereas a median
level of dopamine increases feeding. Indeed, increasing dopamine release in the NAc using a
low dose of amphetamine increases food intake while higher doses decrease food intake in
rats140. In addition, completely depleting dopamine inhibits feeding in mice133. Thus,
neurotensin and -MSH may increase dopamine release to a level that attenuates feeding
behavior, while NPY increases dopamine release to a level that potentiates feeding behavior.
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Overall, how feeding neuropeptides alter dopamine neuron activity to regulate food intake and
food reward and reinforcement is fairly complex, and neuropeptides may modulate dopamine
neuron tonic and bust firing differently or change the overall activity of dopamine neurons and
dopamine release to affect feeding behavior.

6.2

Model 2- Neuropeptides affect specific subpopulations of dopamine neurons to
control distinct behaviors
It is possible that feeding-related neuropeptides regulate specific subpopulations of

dopamine neurons to regulate specific behaviors such as food reward or aversion (Fig. 6.2).
Our data, and others, demonstrate that the same neuropeptide can have both excitatory and
inhibitory effects on VTA dopamine neurons; therefore, it is also possible that neuropeptides
simultaneously activate one subpopulation of dopamine neurons while inhibiting another
subpopulation to regulate different behaviors (Fig. 6.2). Subpopulations of dopamine neurons
projecting to distinct target regions have been shown to regulate different behaviors. For
example, rewards cause an increase in dopamine neuron activity, but subpopulations of
dopamine neurons also increase their activity in response to aversive or stressful stimuli335-338,
and aversive or stressful stimuli cause an increase in dopamine release in the PFC, NAc, and
amygdala338,339. Dopamine neurons encoding aversion seem to project to the PFC, while
dopamine neurons encoding reward project to the NAc. Indeed, a single exposure to cocaine
causes LTP of glutamatergic synapses on lateral shell NAc projecting dopamine neurons, but
does not affect glutamatergic synapses on VTA dopamine neurons projecting to the medial
PFC312. Interestingly, exposure to an aversive stimulus does cause LTP of glutamatergic
synapses on medial PFC projecting dopamine neurons but not on NAc projecting dopamine
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neurons, suggesting PFC projecting neurons encode aversion and NAc projecting neurons
encode reward312. In agreement, excitation of laterodorsal tegmentum inputs to the VTA causes
conditioned place preference while excitation of lateral habenula (LHb) inputs to the VTA
causes conditioned place aversion, and laterodorsal tegmentum inputs excite lateral shell NAc
projecting dopamine neurons, while LHb inputs excite medial PFC projecting dopamine
neurons301. Thus, neuropeptides may modulate the activity of these distinct neuron populations
through different mechanisms or modulate one specific subpopulation of dopamine neurons to
regulate a specific behavior. For example, a neuropeptide that increases food intake and reward
behavior may activate NAc projecting dopamine neurons while inhibiting PFC projecting
dopamine neurons or only activate NAc projecting dopamine neurons to increase feeding and
reward behavior (Fig. 6.2).
The different effects of neurotensin on dopamine neuron activity reported here are all
excitatory and occurred in all dopamine neurons tested. Nevertheless, a recent study has also
shown that neurotensin has inhibitory actions on SNc dopamine neurons. Neurotensin increases
GABAergic transmission on SNc dopamine neurons by increasing GABAA currents through an
increase in GABA release while simultaneously decreasing GABAB currents in the same
neuron331. However, it is unknown whether neurotensin has similar inhibitory effects in the
VTA. In addition, neurotensin has also been shown to attenuate evoked EPSCs in VTA
dopamine neurons333, but one study suggests neurotensin potentiates EPSCs340, while another
suggests neurotensin specifically potentiates NMDAR EPSCs and attenuates AMPAR
EPSCs332. It is unknown if the inhibitory and excitatory effects of neurotensin occur in different
populations of dopamine neurons, or if neurotensin modulates one distinct population of
dopamine neurons to regulate behavior. NTS1 is the primary receptor expressed in VTA
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dopamine neurons, and these NTS1 neurons primarily project to the ventral striatum and
adjacent regions187,341. NTS1 neurons do not project to the PFC or hippocampus and only send
minor projections to the amygdala187,341. Therefore, it is very unlikely that neurotensin
significantly affects the dopamine neurons projecting to these brain regions, although
neurotensin may affect these dopamine neurons through an indirect presynaptic mechanism.
Overall, it seems that intra-VTA neurotensin primarily affects food intake and reward behavior
by activating dopamine neurons projecting to mesolimbic regions.
I have reported that NPY has both excitatory and inhibitory effects on dopamine
neurons. All three effects of NPY occurred in only a subset of dopamine neurons tested, so it is
possible that NPY affects distinct subpopulations of dopamine neurons through different
mechanisms. For example, NPY may excite NAc projecting dopamine neurons and inhibit PFC
projecting dopamine neurons to increase food reward and suppress a stress response. Indeed,
rats will endure aversive stimuli in order to obtain palatable high-calorie foods129,130, and hunger
attenuates pain through NPY signaling in the lateral parabrachial nucleus342. Thus,
neuropeptides that increase food intake, such as NPY, may suppress the activity of brain regions
encoding aversion and stress while activating feeding circuits to increase food intake when the
food is highly rewarding or during an energy deficit. The target sites of dopamine neurons
expressing NPY receptors are unknown, so additional experiments are needed to determine
whether NPY affects subpopulations of dopamine neurons through distinct mechanisms to
regulate different behaviors.
In contrast to NPY and neurotensin, only an excitatory effect of -MSH on VTA
dopamine neuron activity has been reported. It is possible that -MSH also has inhibitory
effects on VTA dopamine neurons. For example, -MSH-induced increases in dopamine
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neuron activity may increase the somatodendritic release of dopamine in the VTA and inhibit
neighboring dopamine neurons through dopamine mediated D2R IPSCs. MC3Rs are only
expressed in a subset of VTA dopamine neurons225. Therefore, -MSH may regulate a distinct
subpopulation of dopamine neurons. The projection targets of MC3R-expressing VTA
dopamine neurons are currently unknown, but our preliminary data suggest that MC3R VTA
neurons project to the NAc but not to the PFC. Thus, it seems that -MSH likely decreases
food intake and reward behavior primarily by activating MC3R neurons projecting to the NAc,
but -MSH may also regulate VTA MC3R neurons projecting to other brain regions through an
indirect presynaptic mechanism.

6.3

Model 3- Neuropeptides regulate VTA glutamate and GABA neuron activity
It is possible that feeding neuropeptides regulate food intake and food reward by

changing the activity of VTA GABA and glutamate neurons in addition to dopamine neurons,
as the VTA contains GABA and glutamate neurons, and dopamine neurons that co-release
either GABA or glutamate (Fig. 6.3). Activating VTA GABA or glutamate neurons has been
shown to affect food intake, reward behavior, and aversion. For example, activation of VTA
glutamate neurons is reinforcing33,343, and causes a real time place preference343. However, the
effect of VTA glutamate activation on behavior depends on the specific population of VTA
glutamate neurons activated. Indeed, in contrast to the above studies, specifically activating
LHb projecting or NAc projecting VTA glutamate neurons causes real-time place avoidance344346

(Fig. 6.3A). Activating local VTA glutamate interneurons increases glutamatergic

transmission onto VTA dopamine neurons and activates dopamine neurons (Fig. 6.3B); thus, it
has been hypothesized that activating local VTA glutamate interneurons increases reward
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behavior through activation of dopamine neurons, whereas activating LHb or NAc projecting
VTA glutamate neurons causes aversion33,343,346 (Fig. 6.3).
Activating VTA GABA neurons also affects reward and aversion behavior.
Unsurprisingly, the effect of VTA GABA neuron activation on behavior is opposite to VTA
glutamate neuron activation. Indeed, activating VTA GABA neurons causes conditioned place
aversion347 and decreases reward consumption348. In addition, inhibiting VTA GABA neurons
increases reward behavior349. Activating local VTA GABA interneurons increases GABAergic
transmission onto VTA dopamine neurons and inhibits dopamine neurons348. Therefore,
activating local VTA GABA interneurons may decrease reward behavior and reward
consumption by inhibiting dopamine neurons (Fig. 6.3B). Conversely, specifically activating
LHb projecting VTA GABA neurons increases reward behavior (Fig. 6.3A). For example,
activation of LHb projecting VTA GABA neurons is reinforcing and causes real time place
preference345,350. Overall, activation or inhibition of different populations of VTA GABA and
glutamate neurons affects reward consumption, reward behavior, and aversion, and one way
neuropeptides may interact with the mesocorticolimbic dopamine system to regulate behavior
and food intake is through modulation of VTA GABA and glutamate neuron activity (Fig. 6.3).
It is unknown whether NPY, neurotensin, or -MSH modulates the activity of VTA
glutamate and GABA neurons, but there is some evidence suggesting that these neuropeptides
do regulate their activity. For example, the neurotensin receptor NTS1 is expressed in LHb
projecting VTA neurons341, and VTA GABA and glutamate neurons project to the LHb but
dopamine neurons do not32-34,350. Intra-VTA neurotensin may increase the activity of these LHb
projecting GABA or glutamate neurons through NTS1, as I have shown that neurotensin
induces an excitatory current in VTA dopamine neurons234 which is mediated by the NTS1
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receptor201-204. It is possible that neurotensin decreases food intake by activating LHb
projecting glutamate neurons, as stimulation of LHb projecting glutamate neurons is
aversive344,345. However, the effect of activating LHb projecting glutamate or GABA VTA
neurons on food intake has not been tested. In addition, neurotensin modulates glutamatergic
transmission in the VTA332,333,340 and GABAergic transmission in the SNc331. Neurotensin may
modulate glutamate and GABAergic transmission by directly affecting the activity of local
VTA GABA and glutamate neurons. Thus, it is possible that neurotensin regulates VTA GABA
and glutamate neuron activity to control feeding and food reward, but further experiments are
needed to test this hypothesis.
NPY likely regulates the activity of GABA and glutamate neurons in the VTA. NPY
has been shown to decrease the firing rate of putative VTA GABA neurons217. Thus, intra-VTA
NPY may increase food reward through inhibition of VTA GABA neurons, as inhibiting VTA
GABA neurons does increase reward behavior349. In addition, I have shown here that NPY
decreases glutamatergic and GABAergic transmission onto a subset of VTA dopamine neurons
through a presynaptic mechanism236. It is possible that NPY directly inhibits local VTA
glutamate and GABA interneurons to decrease presynaptic glutamate and GABA release. Thus,
intra-VTA NPY may modulate food reward by modulating VTA glutamate and/or GABA
neurons, but further experiments are needed to test this hypothesis.
-MSH may also modulate GABA and glutamate neuron activity to regulate feeding. I
have shown that -MSH increases the activity of MC3R-expressing neurons, and MC3Rs are
expressed in both dopamine and non-dopamine neurons225. However, the identity of the nondopamine neurons is unknown. If MC3Rs are expressed in VTA glutamate and/or GABA
neurons, then intra-VTA -MSH may regulate the activity of VTA glutamate and GABA
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neurons to decrease food intake and food reward. For example, our preliminary results suggest
that MC3R neurons project to the LHb; therefore, -MSH may decrease food intake and reward
by activating LHb projecting glutamate neurons. Further experiments are needed to determine
the identity of non-dopamine MC3R-expressing neurons.

6.4

Integration of anorexigenic and orexigenic peptide signals in VTA dopamine
neurons
Numerous feeding related peptides have been shown to interact with the

mesocorticolimbic dopamine system to regulate food intake and food reward168. It is unknown
how VTA dopamine neurons integrate all of these anorexigenic and orexigenic peptide signals
to regulate feeding, or whether one subpopulation of VTA dopamine neurons responds to all
feeding peptides. It is very unlikely that one subpopulation of dopamine neurons responds to all
of these peptides, and different feeding peptides have been shown to affect non-overlapping
populations of dopamine neurons311. Nevertheless, it would be interesting to test if NPY and MSH have opposite effects on the activity of VTA MC3R neurons, because AgRP/NPY
neurons and POMC neurons (-MSH containing) have opposite effects on food intake and
metabolism. In fact, AgRP/NPY neurons inhibit POMC neurons through NPY and
GABA286,351,352. It would also be interesting to test whether NPY or -MSH affect the activity
of NTS1 expressing dopamine neurons, because NTS1 is only expressed in a distinct subset of
mesolimbic VTA dopamine neurons and these NTS1 neurons are hypothesized to be essential
for regulating energy balance187,341. For example, ablation of VTA NTS1 neurons increases
food intake but decreases body weight187. It is likely that -MSH affects the activity of at least
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some of the NTS1 expressing dopamine neurons, because our preliminary results suggest that
the projection pattern of VTA MC3R neurons is similar to that of NTS1 VTA neurons.
It is expected that the effects of anorexigenic and orexigenic neuropeptides on VTA
dopamine neuron activity would be in opposition. Indeed, the effects of neurotensin and NPY
on VTA dopamine neuron activity may be in opposition. Intra-VTA neurotensin and NPY have
opposite effects on food reinforcement170,174, and I have shown that NPY activates a GIRK
current while neurotensin inhibits dopamine and GABA mediated GIRK currents234,236. Hence,
neurotensin may inhibit the NPY-mediated GIRK current. In contrast, the effects of -MSH
and neurotensin on VTA dopamine neuron activity may be complementary as both peptides
have seemingly excitatory effects on VTA dopamine neurons and both peptides decrease food
intake and food reward when injected into the VTA169-173,175. Thus, overall it is unclear how
dopamine neurons integrate all of these feeding-related neuropeptide signals, and additional
experiments are needed to determine how VTA dopamine neurons integrate feeding signals.

6.5

Future directions

6.5.1 Neurotensin
I have shown that neurotensin inhibits GIRK currents mediated by D2Rs and GABAB
receptors234 and this has been verified by additional studies331,353. Future experiments are
needed to test whether neurotensin also inhibits NPY mediated GIRK currents. If neurotensin
specifically inhibits GIRK currents, then it is expected that neurotensin would inhibit the NPY
current. The mechanism of inhibition of neurotensin-induced GIRK currents is still unknown,
and additional experiments are also needed to determine how neurotensin inhibits GIRK
currents. I have discussed possible explanations of how neurotensin inhibits GIRK currents
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above, so I will not go into great detail here. I have shown that neurotensin does not inhibit
GIRK currents through the PKC pathway or through Ca2+ release from intracellular stores, but
have shown that increased intracellular Ca2+ levels do reduce neurotensin-induced inhibition of
GIRK currents234. In addition, Tschumi and Beckstead have shown that neurotensin does not
inhibit GABAB mediated GIRK currents in SNc dopamine neurons through the PKA pathway
or through general kinases and phosphatases as nonspecific kinase and phosphatase blockers do
not affect neurotensin inhibition of GABAB GIRK currents331. Thus, additional experiments are
needed to determine how neurotensin inhibits GIRK currents in VTA dopamine neurons in
order to better elucidate how neurotensin regulates VTA dopamine neuron activity.
6.5.2 NPY
NPY affects VTA dopamine neuron activity through both pre- and postsynaptic
mechanisms, and through mechanisms that both inhibit and excite VTA dopamine neurons. All
of the effects of NPY occurred in only a subset of dopamine neurons tested. Therefore, NPY
may modulate distinct subpopulations of dopamine neurons through different mechanisms.
Future experiments are needed to test this hypothesis, and future experiments should also
determine which specific NPY receptors are expressed in VTA neurons, as well as the
projection targets of these neurons. In addition, the MC3R is only expressed in a subset of VTA
dopamine neurons, and it is unknown if NPY specifically modulates that activity of this distinct
population of dopamine neurons. Thus, further experiments are also needed to test the effect of
NPY on MC3R VTA neurons. Finally, the brain regions from which VTA NPY afferent inputs
may arise from are currently unknown. AgRP fibers do innervate the VTA278 suggesting that
AgRP/NPY neurons project to the VTA. However, additional NPY neuron populations may
also innervate the VTA, and future experiments should determine if NPY neurons from other
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brain regions project to the VTA. These experiments would lead to a better understanding of
how NPY interacts with the mesocorticolimbic dopamine system to control food reward.
6.5.3 -MSH
I have shown that -MSH increases the firing rate of VTA MC3R-expressing neurons,
but how -MSH increases MC3R neuron activity is unknown. MC3Rs are G protein-coupled
receptors that signal through Gs-proteins and thus activate the cAMP pathway223, but there is
also evidence suggesting that MC3Rs are coupled to Gi-proteins and activate MAP kinase
through PI3K signaling313. Future experiments testing the effect of blocking different
intracellular signaling pathways on -MSH-induced increases in MC3R neuron activity are
needed to determine how -MSH increases VTA MC3R neuron activity.
Previous studies have shown that activation of MC3Rs increases intracellular Ca2+ in
neurons and HEK293 cells314-317. Ca2+ is an important regulator of dopamine neuron
excitability, burst firing, and glutamatergic and GABAergic synaptic
plasticity56,57,69,114,118,119,124. Ca2+ also activates sK currents in VTA dopamine neurons, which
are also an important regulator of dopamine neuron firing and burst firing66,69,354. sK currents
are activated by action potential induced Ca2+ influxes and release of Ca2+ from intracellular
stores355,356. CRF and forskolin have been shown to potentiate sK currents and enhance Ca2+
release from intracellular stores through a PKA dependent mechanism in VTA dopamine
neurons116,357,358. As -MSH uses a similar signaling pathway, -MSH may enhance
intracellular Ca2+ release and sK currents through a similar mechanism. Thus, future
experiments should be conducted to determine if -MSH increases sK currents, and
experiments using Ca2+ imaging should be conducted to determine whether -MSH increases
intracellular Ca2+ levels in VTA MC3R neurons.
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-MSH may affect VTA MC3R neuron activity through additional mechanisms not
tested here, such as changing the strength of afferent inputs to VTA MC3R neurons. For
example, previous studies have shown that -MSH and MTII (-MSH analog) change
glutamatergic and GABAergic transmission in different areas of the CNS359-363. -MSH may
also affect glutamatergic and GABAergic transmission on VTA MC3R neurons. Future
experiments testing the effect of -MSH on glutamatergic and GABAergic transmission in
VTA MC3R neurons are needed to determine the effect of -MSH on VTA afferent inputs.
Finally, our results suggest that -MSH likely increases the activity of VTA MC3Rexpressing dopamine neurons, but -MSH may also increase the activity of glutamate and/or
GABA MC3R-expressing VTA neurons. The identity of non-dopamine MC3R neurons is
unknown; thus, future experiments should determine whether GABA and/or glutamate VTA
neurons express MC3Rs, and whether -MSH modulates the activity of dopamine and nondopamine MC3R-expressing VTA neurons through different mechanisms. The additional
experiments described here would further elucidate how -MSH acts at the cellular level in the
VTA to regulate food intake and food reward.

6.6

Summary to Conclusion
I have shown that neurotensin, NPY, and -MSH affect VTA dopamine neuron activity

through multiple mechanisms and have described three possible models as to how these
peptides may alter the activity of VTA neurons to control food intake and food reward. Feeding
neuropeptides acting in the VTA most likely do not regulate food intake and food reward
through one mechanism or through only one of the methods described above. For example, one
feeding peptide may regulate the activity of a distinct subpopulation of dopamine neurons (Fig.
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6.2), affect tonic and burst dopamine neuron firing differently (Fig. 6.1), and affect VTA
glutamate and/or GABA neuron activity to control food intake and reward behavior (Fig. 6.3).
In addition, the different effects of neuropeptides on the mesocorticolimbic dopamine system
may affect different feeding and reward behaviors, so one neuropeptide acting in the VTA may
not affect both food intake and food reward but only affect one or the other. Thus, how feedingrelated neuropeptides affect VTA dopamine neuron activity to control food intake and reward is
complex, but the experiments presented here have added to the existing body of knowledge and
advanced the collective understanding of how hypothalamic feeding-related neuropeptides
interact with the mesocorticolimbic dopamine system to regulate food intake and food reward.
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6.7

Figures

Figure 6.1: Model 1- Neuropeptides regulate tonic and burst firing through different
mechanisms.
Feeding-related neuropeptides may regulate food intake and food reward by specifically
affecting either tonic or burst firing in VTA dopamine neurons or by decreasing tonic firing but
increasing burst firing and vice versa. Evoking tonic firing decreases reward consumption
whereas evoking burst firing increases reward behavior in VTA dopamine neurons.
Anorexigenic neuropeptides such as neurotensin and α-MSH may decrease food intake and
reward behavior by increasing tonic firing and decreasing burst firing. Orexigenic
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neuropeptides such as NPY may increase food intake and reward behavior by decreasing tonic
firing and increasing burst firing in VTA dopamine neurons.

Figure 6.2: Model 2- Neuropeptides affect specific subpopulations of dopamine neurons to
control distinct behaviors.
Feeding-related neuropeptides may regulate food intake and food reward by regulating the
activity of specific subpopulations of dopamine (DA) neurons to regulate specific behaviors.
NAc projecting dopamine neurons encode reward behavior while PFC projecting dopamine
neurons encode aversion and stress. Anorexigenic neuropeptides such as neurotensin (NT) and
α-MSH may decrease food intake and reward behavior by activating PFC projecting dopamine
neurons and inhibiting NAc projecting dopamine neurons. Orexigenic neuropeptides such as
NPY may increase food intake and reward behavior by inhibiting PFC projecting dopamine
neurons and activating NAc projecting dopamine neurons.
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A

B

Figure 6.3: Model 3- Neuropeptides regulate VTA glutamate and GABA neuron activity.
Feeding-related neuropeptides may regulate food intake and food reward by changing the
activity of VTA GABA and glutamate neurons in addition to dopamine (DA) neurons. A.
Activation of NAc and LHb projecting VTA glutamate neurons causes aversion whereas
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activation of LHb projecting VTA GABA neurons increases reward behavior. Anorexigenic
neuropeptides (such as neurotensin (NT) and α-MSH) may decrease food intake and reward
behavior by activating LHb and NAc projecting glutamate neurons and inhibiting LHb
projecting GABA neurons. Orexigenic neuropeptides (such as NPY) may increase food intake
and reward behavior by inhibiting NAc and LHb projecting glutamate neurons and activating
LHb projecting GABA neurons. B. Activation of locally projecting VTA glutamate neurons
increases reward behavior through excitation of VTA dopamine neurons whereas activation of
locally projecting VTA GABA neurons causes aversion and decreases reward consumption
through inhibition of VTA dopamine neurons. Anorexigenic neuropeptides (such as NT and αMSH) may excite VTA GABA neurons and inhibit VTA glutamate neurons to decrease food
intake and reward behavior. Orexigenic neuropeptides (such as NPY) may inhibit VTA GABA
neurons and excite VTA glutamate neurons to increase food intake and reward behavior.
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